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Abstract 
Type 2 Diabetes is responsible for a global public health burden and affects an estimated 30 
million people in the United States, many of whom have difficulty reaching glycemic targets.  
Approximately 15 percent of the diabetic patients in the Family Health Clinic have an A1C 
above 8.0.  Telemedicine shows promise in improving glycemic control and enhancing access to 
care.  Current literature supports the use of telemedicine to improve glycemic outcomes.  The 
purpose of this project was to assess the acceptability and effectiveness of a provider 
implemented intense telephonic follow-up program on glycemic outcomes and self-management 
of patients with uncontrolled Type 2 Diabetes.  This quality improvement project used a pre-test 
post-test design using laboratory and survey data collection methods to measure hemoglobin 
A1C, diabetes self-care, and a post-test provider satisfaction survey.  Over a 3-month period, 
patients meeting criteria for the intervention were provided with telephonic provider follow-up 
visits at 2-3 week intervals including education on lifestyle changes, medication management 
and self-care.  The mean change in A1C was statistically and clinically significant.  The mean 
change in total self-care survey score was also significant.  The data indicated that utilization of 
telemedicine follow-up improved clinical outcomes for Type 2 Diabetics. 
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Chapter One: Overview of the Problem 
 The diagnosis of Type 2 Diabetes (T2DM) is life changing and can dramatically impact 
the quality of life and life expectancy of those afflicted (Franco et al., 2007).  Diabetes represents 
a massive and global public health burden (Lee, Chan, Chua, & Chaiyakunapruk, 2017).  Despite 
the vast amount of money, resources, research, and medications focused on addressing this 
disease, outcomes often continue to be poor, and many patients never reach their treatment goals 
(Schmittdiel et al., 2008).  Limited access to care, time constraints, and geographic distance often 
reduce the opportunity for providers to individualize and address all the aspects of diabetes care 
and management.  To address this barrier, the use of telemedicine in clinical practice offers great 
potential for improving outcomes in patients with Type 2 Diabetes (Gervera & Graves, 2015).  
Telemedicine visits can be accomplished regardless of geographic constraints and potentially can 
be scheduled more frequently than in-clinic visits.  Many studies that have investigated 
telemedicine’s impact upon diabetic care have shown positive clinical outcomes such as 
improved glycemic control evidenced by reductions in Hemoglobin A1C (A1C) and improved 
diabetes self-management behaviors when compared to usual care (Crowley et al., 2016; Faruque 
et al., 2017; Stone et al., 2010; Trief et al., 2013, Wu et al., 2010). 
 The purpose of this project was to examine the acceptability and effectiveness of a 
provider-implemented intensive telemedicine follow-up program to improve glycemic outcomes 
and self-care in adult patients with poorly controlled Type 2 Diabetes, in addition to usual care.  
This chapter includes an overview of the problem of Type 2 Diabetes, the clinical significance of 
the disease, and the specific background and impacts of diabetes: globally, nationally, within 
Alaska, and particularly within the military treatment facility where this project will be 
conducted. 
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Background    
Global and national.  Diabetes Mellitus impacts public health on a global level.  Over 
415 million people worldwide have diabetes, and that number will likely double by 2040 if 
current trends continue (Lee et al., 2017).  Global health costs related to diabetes are estimated to 
reach more than $300 billion by 2025 (Su et al., 2016).  The Centers for Disease Control and 
Prevention (CDC) estimated that more than 30 million people in the United States currently have 
diabetes (2018).  Diabetes also has an impact on the economy beyond healthcare costs.  Reduced 
work productivity in the U.S. due to the effects of diabetes was estimated at $58 billion (Polisena 
et al., 2009).  People with diabetes have a life expectancy that is six to eight years shorter than 
people who do not (Rasmussen, Lauszus, & Loekke, 2016).   
Across the United States within the Veterans Affairs Health System, 30% of all 
prescriptions written are for diabetic patients, and oral diabetes medications alone result in 
annual pharmacy costs in excess of $103 million (Gervera & Graves, 2015).  Within the U.S. Air 
Force, over 50,000 beneficiaries treated at Air Force medical facilities have diabetes and the 
majority are not on active duty (Sauerwein & True, 2016).  The Military Health System overall 
has a 13% prevalence of diabetes (United States Department of Veterans Affairs/United States 
Army Medical Command Office of Evidence Based Practice [VA/Army], 2017), reflecting 
similar patterns of diabetes to the U.S. at large.   
Alaska.  Diabetes is a major public health problem within the state of Alaska.  Statistics 
show that 7.5% of adults in Alaska are diabetic (approximately 90% of those are Type 2), and 
the prevalence has increased significantly in recent years (Alaska Department of Health and 
Social Services [AK DHSS], 2019).  According to the Alaska Department of Health and Social 
Services (2019), diabetes (including Type 1 and Type 2) is the eighth leading cause of death 
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within Alaska and resulted in 70,000 hospital visits in 2016.  Of particular concern is that only 
one-third of Alaskan diabetics meet specific quality of care standards, such as being up to date 
on lab and health screenings (AK DHSS, 2019).  Meeting care standards such as having an A1C 
within individualized goal range, performing recommended screenings, and maintaining self-
care measures have all been shown to improve clinical outcomes (CDC, 2018). 
673rd medical group.  At Joint Base Elmendorf-Richardson (JBER) in Anchorage, 
Alaska, the 673rd Medical Group provides primary, specialty, and inpatient care to over 35,000 
beneficiaries who reside across the state of Alaska.  Beneficiaries include active duty military 
personnel from all branches and their dependent spouses and children, as well as military retirees 
and their dependent spouses.  Patients eligible for care at this military treatment facility may 
reside in Anchorage and Matanuska-Susitna Borough as well as more distant communities such 
as Valdez (300 miles), Kodiak (250 mile flight), Seward (170 miles), Homer (220 miles), 
Glennallen (180 miles) and many small rural communities in between.  A number of retirees and 
dependents split their time between Anchorage and working on the North Slope of Alaska (660 
mile flight) where medical care is quite limited, or they live out of state seasonally in the lower 
48 states.  The Army maintains a separate medical clinic on Fort Richardson for active duty 
troops but does not provide services for dependents or retirees.  There are also military treatment 
facilities in Fairbanks that serve the Interior of Alaska.  At present 1,856 diabetic patients are 
receiving care at the 673rd Medical Group on Joint Base Elmendorf-Richardson in Anchorage, 
and of that population approximately 15% have an A1C over 8.0, indicating poor control of this 
disease (Carepoint, 2019).  The vast majority of patients with diabetes are not on active duty.  
With a population of patients spread throughout the state of Alaska, distance and geography 
present a major barrier to care for some patients.   
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Telemedicine.  Telemedicine is defined as “the use of telecommunications technology to 
provide clinical care and promote disease self-management” (Gervera & Graves, 2015, p.1).  
Telemedicine is a broad term that can involve a variety of technological methods to connect with 
patients.  Telemedicine modalities include the use of telephone visits, video conferencing, 
internet applications, secure messaging/email, remote monitoring, and various electronic health 
applications (Gervera & Graves, 2015; VA/Army, 2017).   
Telemedicine can be used to increase access to care and improve convenience for 
patients, especially those needing more frequent follow-up and outcomes monitoring (Gervera & 
Graves, 2015).  Teeter and Kavookijan (2014) discussed the impact of access barriers to diabetes 
care especially for people living in rural areas where access to in-person visits can be 
challenging.  These access barriers can result in reduced opportunity for disease education and 
management.  In Alaska, the vast geography of the state along with extreme weather conditions 
certainly contribute to this problem, even within the military beneficiary population which can be 
spread throughout the state as noted above.  Telemedicine can be particularly valuable in patients 
with uncontrolled diabetes who need a more intense level of care.  Crowley et al. (2016) noted 
that patients with an A1C of greater than 9.0 are at the highest risk of diabetic complications, and 
their study demonstrated that the telemedicine intervention group had a significant reduction in 
A1C levels of 1.3%, compared to 0.3% in the usual care group at 3 months, and also 
demonstrated improved diabetes self-management scores.  The United States Department of 
Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of 
Type 2 Diabetes Mellitus in Primary Care [VA/Army] (2017) states that telemedicine modalities 
can and should be used to enhance clinical outcomes in the management of Type 2 Diabetes.  At 
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present this recommendation has not been fully implemented within the Family Health Clinic at 
the 673rd Medical Group. 
Clinical Significance 
Approximately 1.4 million new cases of diabetes are diagnosed each year, and of those 
cases American Indians/Alaska Natives have the highest incidence of diabetes, followed by 
blacks, Hispanics, and Asians (CDC, 2018).  Type 2 Diabetes occurs when the body no longer 
makes adequate insulin due to beta cell dysfunction in the pancreas, or when it can no longer 
effectively use insulin to regulate blood glucose levels due to insulin resistance (Kahn, 2003).  
The vast majority of people with diabetes, approximately 90% of all cases in Alaska, are 
classified as Type 2 (AK DHSS, 2019).  Type 2 Diabetes is often related to lifestyle factors, 
including obesity (AK DHSS, 2019; CDC, 2018; VA/Army, 2017).  
Diabetes contributes to significant morbidity and mortality.  People with both Type 1 and 
Type 2 diabetes are at higher risk of developing high blood pressure, high cholesterol, stroke, 
chronic kidney disease, heart attack, blindness, and neuropathy which can lead to limb 
amputations (CDC, 2018; VA/Army, 2017).  Type 1 and Type 2 diabetics have a two to four-
fold increased risk of cardiovascular disease overall (VA/Army, 2017).  Diabetes in general is 
the seventh leading cause of death in the U.S. (CDC, 2018).  Sixty percent of non-traumatic limb 
amputations are the result of diabetes (Gervera & Graves, 2015).   
  A 0.5% reduction in A1C is generally considered clinically significant and the gold 
standard for assessing clinical outcomes according to multiple organizations including the 
American Diabetes Association and the National Institute for Health and Clinical Excellence 
(Little et al., 2013).  However, even slightly lower reductions in A1C may provide clinical 
benefit to some patients (Little et al., 2013).   
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Evidence of telemedicine.  It is clear that Type 2 Diabetes has a significant impact on 
health within populations, healthcare systems, and individuals.  As health professionals we are 
obligated to use the best evidence to improve practice and ensure the best possible outcomes for 
our patients.  A number of systematic reviews, meta-analyses, and randomized controlled trials 
(RCT’s) have provided evidence for the use of telemedicine to improve outcomes in patients 
with Type 2 Diabetes (Chamany et al., 2015; Faruque et al., 2017; Lee et al., 2017; Polisena et 
al., 2009; Rasmussen et al., 2015; Stone et al., 2010; Su et al., 2016; Teeter & Kavookijan, 2014; 
Trief, et al., 2013).  
In a systematic review and meta-analysis, Polisena et al (2009) compared clinical 
outcomes between telehealth and usual care groups; the authors reported there were significant 
improvements in hemoglobin A1C levels within the telehealth groups.  Teeter and Kavookijan 
(2014) conducted a systematic review which demonstrated more broadly that telephone based 
motivational interviewing for medication adherence led to improved medication compliance in 
five of the nine studies that were included.  Lee et al. (2017) conducted a systematic review and 
meta-analysis of over 20,000 patients which demonstrated that telemedicine provided a 
significant improvement in A1C levels over usual care with a mean difference of -0.43% (p < 
.001).  Su et al. (2016) conducted a meta-analysis of 55 RCT’s and demonstrated a significant 
improvement in A1C for patients receiving telemedicine services compared to those not served 
by telemedicine (Hedges g = -0.48, p < .001).  Trief et al. (2013) conducted a five-year study, 
titled the Informatics for Diabetes Education and Telemedicine (IDEATel) Demonstration 
Project, which utilized various elements of telemedicine to improve self-care in minority 
populations. The study showed the telemedicine group was more adherent to self-care behaviors 
than the usual care group, based on the Summary of Diabetes Self Care Scale (SDSCA).   
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Current Clinical Problem 
 The clinical problem for this project was identified in practice at the Family Health Clinic 
at the 673rd Medical Group, Joint Base Elmendorf-Richardson, Anchorage, Alaska.  The 
population of this clinic includes Department of Defense Tricare beneficiaries which includes 
active duty military members, retirees, and their dependents.   
 Tricare insurance allows members to receive free treatment and medications when 
patients are seen at a military treatment facility.  Tricare beneficiaries who are seen off base have 
reasonable copays for care.  The reduced cost of care limits the financial barriers to care that 
many Americans experience.  Due to the lack of endocrinologists in Alaska, few Type 2 Diabetic 
patients receive specialist management – currently only two endocrinologists in the region accept 
Tricare patients.  The average empanelment per provider within the Family Health Clinic is 
1,250 patients but can rapidly increase when providers deploy.  As previously stated, the entire 
medical group has 1,856 patients enrolled with a diagnosis of diabetes as of June 2019, of which 
264 had a most recent A1C of greater than or equal to 8.0 (Carepoint, 2019).  The JBER Family 
Health Clinic manages many of these patients, with smaller numbers seen in the Internal 
Medicine and Pediatric Clinics.  Family Health had an enrollment of 1,146 patients with diabetes 
(June 2019) with the vast majority having Type 2 Diabetes (Carepoint, 2019).  The estimated 
annual cost of these enrollees for care is approximately $9.9 million dollars, and the estimated 
pharmacy cost is $2.4 million (Carepoint, 2019). 
 Despite having access to numerous resources, including free/low cost healthcare visits, 
free medications, and access to care standards generally enabling patients to schedule a future 
clinic visit within seven days, many patients still have poor outcomes related to diabetes and did 
not meet care standards.  As noted previously, approximately 15% of the patients (n = 264) have 
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an A1C above 8.0.  Military medicine utilizes the National Committee for Quality Assurance 
(NCQA) Healthcare Effectiveness Data and Information Set (HEDIS) metrics to track clinical 
quality of care (Carepoint, 2019; NCQA, 2019).  According to this HEDIS data the Family 
Health Clinic does not consistently meet A1C clinical outcome metrics (Carepoint, 2019).   
 The VA/DOD Clinical Practice Guidelines (VA/DOD CPG) for the Management of Type 
2 Diabetes Mellitus in Primary Care (2017) provide standards for best practices within primary 
care and recommend “offering one or more types of bidirectional telehealth interventions (health 
communication via computer, telephone, or other electronic means) involving licensed 
independent practitioners to patients selected by their primary care provider as an adjunct to 
usual patient care” (p.21).  These guidelines also provide recommendations on target ranges for 
A1C based on patient factors and provider discretion, therapeutic lifestyle changes, and 
medication management strategies.  Despite the evidence-based recommendations within the 
CPG, telemedicine has not been fully or consistently implemented within the Family Health 
Clinic as a care strategy for managing diabetes.  The CPG also states that support for diabetes 
self-management education (DSME) should be individualized to the patient and use multiple 
different methods to reach patients (VA/Army, 2017).  DSME practices include “knowledge 
about diabetes and treatment options, medications, nutrition, exercise, hypoglycemia, monitoring 
of glucose and HbA1c, psychosocial and behavioral components, risk reduction, foot care, 
smoking cessation, chronic complications, and sick day management”  (VA/Army, 2017, p.21).     
 An initiative called RESET which stands for “Reward Efficiency, Set Priorities” was 
started at JBER in late 2017, and involved offering limited telephonic follow-up visits to patients 
instead of face to face clinic appointments.   In general, these visits were used for simple acute 
conditions or follow-ups where a physical exam was not needed.  These virtual visits have 
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generally not been used for more complex issues such as diabetes follow-up, and no specific 
program exists to guide provider-driven diabetes telemedicine practice.  RESET was sidelined 
with the transition to Defense Health Agency (DHA) management in late 2019.    
 Anecdotal evidence has shown increased patient satisfaction, reduced wait 
times/improved access to care, and increased provider comfort levels with the limited 
telemedicine practices utilized thus far.  Ongoing changes to the Military Health System, 
including transition to management by the Defense Health Agency on October 1, 2019 have 
increased the need for evidence that telemedicine can provide improved clinical outcomes for 
patients.  The major burden of diabetes and the need for frequent follow-ups for those with 
poorly controlled disease has created a significant problem which supports the need for this 
clinical quality improvement project. 
 Key stakeholders for this project include patients with poorly controlled Type 2 Diabetes, 
Family Health Clinic providers (physicians, nurse practitioners, and physician assistants), clinic 
support staff (registered nurses, medical technicians), and the larger medical group including 
673rd Medical Group executive leadership.  Diabetic management is multidisciplinary, therefore 
additional stakeholders include clinical pharmacists who assist with complex medication 
management, Health Manager Registered Nurses who provide diabetes education, and Health 
Care Integrators who monitor diabetes statistics and care utilization.  
 Current practice for Type 2 Diabetes management in the Family Health Clinic involves 
face to face visits and an A1C lab test a minimum of every six months for well controlled 
diabetics, and every three months for poorly controlled diabetics.  Historically, poorly controlled 
patients have only been seen every three months, with no follow-up or education between clinic 
visits.  Often patients do not follow-up as recommended, and one reason cited is the 
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inconvenience of traveling to the clinic – whether due to work schedule, geographic distance, 
weather, or wait times.  Virtual visits are not systematically used for most diabetic follows ups at 
this time which is a gap in the current clinical practice recommendations.  Health Manager 
Registered Nurses engage newly-diagnosed patients with diabetes for education at initial 
diagnosis but only provide limited follow-up with patients who have an A1C over 9.0 at this 
time, creating a gap for poorly controlled patients with lower A1Cs.  Dieticians are also engaged 
at diagnosis, but do not provide any consistent follow-up care unless patients are referred back 
by their providers.  The Clinical Pharmacist may be engaged by the primary care manager 
(PCM) when more intense medication management is needed, but they only provide follow up in 
the clinic every few months and do not perform telemedicine visits.   This demonstrates a gap in 
care that could be bridged through provider directed telemedicine visits. 
Question Guiding Inquiry 
 A PICOT question is a way to systematically describe the components of a clinical 
question and stands for Population, Intervention, Comparison, Outcomes, and Time frame 
(Stillwell, Fineout-Overholt, Melnyk, & Williamson, 2010).  For this clinical problem, the 
PICOT question was: in adult patients with poorly controlled Type 2 Diabetes receiving care in 
the Family Health Clinic; will a provider-implemented intense telemedicine follow-up program, 
in addition to usual care, be acceptable to providers, and improve glycemic outcomes as well as 
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Conclusion 
 Diabetes represents a major public health burden, and having uncontrolled diabetes 
significantly increases the risk of poor clinical outcomes.  There are many potential barriers to 
achieving optimal glycemic outcomes.  Although clinical practice guidelines and evidence-based 
literature support the use of telemedicine to improve diabetes outcomes, there has been 
inconsistent utilization of these modalities in the Family Health Clinic.  This project seeks to 
determine the acceptability and effectiveness of a provider-driven intense telemedicine follow-up 
program on glycemic outcomes and self-care in poorly controlled Type 2 Diabetics.     
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Chapter Two: Review of the Literature 
 The foundation of evidence-based practice is performing a comprehensive review of the 
literature to determine what evidence is available to support clinical practice and implement 
process improvement initiatives that will lead to the best possible patient outcomes.  This project 
addresses the use of telemedicine to improve glycemic outcomes and self-management in adults 
with poorly controlled Type 2 Diabetes.  A comprehensive literature review was performed to 
determine what evidence is available to support this practice and to develop the project focus and 
proposal.  This chapter reviews the available evidence describing the use of telemedicine to 
improve diabetes outcomes.  Search strategies used and evaluation of the quantity and quality of 
evidence for this topic is addressed, as well as synthesis of the body of evidence.   
Methodology 
 A search strategy was developed based on the PICOT question to locate relevant 
literature within multiple databases.  The literature review targeted evidence such as systematic 
reviews, meta-analyses, and randomized controlled trials relevant to diabetes and telemedicine 
and glycemic outcomes as measured by hemoglobin A1C as well as self-management.  Once the 
individual articles were selected, each was evaluated based on specific criteria as described 
below to assess for quality and clinical relevance to the PICOT question.     
 Strategies.  Key databases were searched including PubMed, CINAHL, Cochrane 
Database, and Google Scholar.  Keywords searched included “Diabetes Mellitus Type 2”, 
“Telemedicine”, “Telehealth”, “Outcomes”,  “A1C”, and “Self-Management”.  Different 
combinations of the search terms were utilized, and MeSH terms were selected within PubMed.  
In CINAHL search terms were exploded to broaden search results.   Search terms were combined 
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using AND/OR to narrow results.  Within each database limiters were used to limit selections to 
peer-reviewed articles, English language, adults, and the timeframe was limited to locate the 
most current evidence.  When broader search criteria were initially used, several studies were 
located that were more than five years old, and those were assessed to see if they contained 
sentinel information that warranted inclusion and were included if applicable.  Additional 
limiters were used when available in each database to specify Randomized Controlled Trials, 
Systematic Reviews, and Meta-Analyses.  Titles and then abstracts were reviewed for content 
relevance to the clinical topic.  Applicable studies that addressed the topic were further reviewed 
for inclusion. 
 In general, the search was focused on locating higher levels of evidence such as 
Systematic Reviews, Meta-Analyses, and Randomized Controlled Trials (level one and two 
evidence).  Articles selected for review had to be relevant to the use of telemedicine modalities 
to improve glycemic outcomes (in particular A1C as a measurement of glycemic control) or 
diabetes self-care management in adult patients with Type 2 Diabetes.  Select articles including 
both Type 1 and Type 2 Diabetes were included because of data relevant to the Type 2 Diabetes 
population.  Articles including gestational diabetes and other less common forms of diabetes 
were excluded.  Articles that exclusively addressed mobile applications (mHealth), remote 
telemonitoring devices, or internet-based modes of telecommunication were discarded as these 
technologies were not consistent with the real time telephonic modality of this intervention.  The 
studies included for final review had to assess A1C as a primary measure for glycemic control as 
the clinical outcome or improved diabetic self-care measures.    
 PubMed was the first database searched.  An initial search was conducted without MeSH 
terms with the subject keywords “Diabetes Mellitus AND telemedicine” which revealed 1,506 
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studies.  This search was then refined using the limiters of English language, adult 19+, and 
publication type limited to systematic reviews which led to 20 results with only one being 
relevant after abstract review.  Adding RCT’s to the limiters led to 78 articles, of which seven 
abstracts met criteria.  MeSH terms were then used in the search including “diabetes mellitus, 
type 2”, “telemedicine”, and “treatment outcomes” to expand the search.  Initially a search was 
conducted utilizing MeSH terms “diabetes mellitus, type 2 AND telemedicine OR telehealth 
AND outcomes” which resulted in 6,974 citations.  These results were immediately narrowed by 
using the limiters of five years, English language, adults 19+, humans, and adding article type as 
systematic review, RCT, and meta-analysis which reduced the number of articles to 779.  Further 
narrowing occurred by adding “A1C” to the search string, which reduced the total to 19. No 
additional articles were found when adding “Self-Management”.  Abstracts were reviewed for 
inclusion criteria relating to the PICOT question and a total of seven new articles were located.  
Duplicates were removed, which left four articles for review.  Eleven total articles were retained 
from the PubMed search.   
 CINAHL was then searched using the keywords of “diabetes mellitus type 2” which was 
then exploded, with 26,216 articles found.  The keyword “telemedicine OR telehealth” was 
searched and then exploded, which returned 3,496 articles.  When these two terms were 
combined with AND a total of 103 articles remained.  Utilizing the limiters for publication type 
“systematic reviews and RCT’s” the total was narrowed down to 39 studies.  Titles and abstracts 
were reviewed, and studies that did not meet criteria were eliminated.  Multiple duplicate studies 
were found, and once these were eliminated four new studies were found that met the criteria for 
inclusion resulting in a total of 15 studies retained from PubMed and CINAHL.  
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 Cochrane systematic reviews database was searched under the subject heading “diabetes 
and telemedicine”, as well as combinations of “diabetes mellitus, type 2” and “telemedicine” or 
“telehealth” and “outcomes” and no relevant systematic reviews were located pertinent to this 
topic in Cochrane. 
 Finally, Google Scholar was searched utilizing the keywords “diabetes mellitus AND 
telemedicine” with a limiter of five years.  Google Scholar did not have as many precise limiters 
as the other databases, so the initial search returned over 17,000 hits.  Utilizing the feature “sort 
by relevance” and refining the search to “diabetes mellitus AND telemedicine AND outcomes 
AND systematic review” led to 14 relevant articles, of which 11 were duplicates and three were 
included for review after title and abstracts were assessed. 
 A total of 18 articles were located within PubMed, CINAHL, and Google Scholar.  One 
additional article was added based on hand search for a grand total of 19 articles reviewed. 
The United States Department of Veterans Affairs and Department of Defense published a 
clinical practice guideline for the Management of Type 2 Diabetes Mellitus in Primary Care 
(2017) which was developed through a systematic review with recommendations made by a 
panel of clinical experts.  This CPG was included in the literature review as well, since it 
provides evidence for the use of telemedicine to improve diabetes clinical outcomes.  The gray 
literature and theses were not searched for this study because higher level of evidence was 
preferred and available to drive clinical decisions.   
 Data evaluation.  As mentioned above, articles selected for review had to address the 
key elements of the PICOT question, namely improving outcomes (specifically glycemic control 
as measured by A1C; or diabetes self-care management) in adult Type 2 Diabetics utilizing 
telemedicine strategies.  Once an article was selected for further review based on title and 
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abstract, it was read through several times with key points highlighted and outlined.  The Rapid 
Critical Appraisal Checklists from Fineout-Overholt and Melnyk (2005) were used to assess 
quality of the studies.  Particular attention was given to the level of evidence, description of 
study methods and statistical analysis.  Findings were assessed for both statistical and clinical 
significance.  Although many of these studies measured more than one variable, only results 
relevant to A1C or diabetic self-care were included for purposes of review.   
 A 0.5% reduction in A1C has been considered clinically significant according to multiple 
organizations including the American Diabetes Association and the National Institute for Health 
and Clinical Excellence (Little et al., 2013).  As such, outcomes that showed a mean reduction in 
A1C of 0.5% or greater were considered to have a stronger clinical relevance.   
Critical Appraisal 
 The data and overall quality of each study were reviewed as described above, and all 
relevant points were summarized in the Evidence Table (Appendix A) and Synthesis Table 
(Appendix B) to search for common themes of evidence.  Common themes were then assessed 
between articles and the overall quality of evidence was assessed.   
 Evaluation.  Nineteen articles were assessed for evidence on the use of telemedicine in 
managing Type 2 Diabetes.  The majority of the sources were systematic reviews or randomized 
controlled trials, with one outlier retrospective cohort study that tested the effect of an Endocrine 
Nurse Practitioner-provided telemedicine intervention, which was consistent with the purpose 
and approach of this project.  The systematic reviews were analyzed to determine if there was an 
overlap with the other research studies located and overall there were no significant overlaps.  
Faruque et al. (2017) included the Crowley et al. (2016) and Rasmussen et al. (2015) studies in 
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their systematic review.  Lee et al. (2017), Polisena et al. (2009), Su et al. (2016), and Wu et al. 
(2010) had no crossover studies.  Zhai et al. (2014) cited Trief et al. (2013) in their review.  
There were no overlaps noted with the VA/DOD Clinical Practice Guidelines (2017).  
 All of the reviewed articles were fairly heterogenous in design, population/sample sizes, 
health professionals performing the interventions, and location.  Additionally, all of the studies 
dealt with utilization of one or more telemedicine modalities, with some comparing the impact of 
multiple different modalities (Faruque et al., 2017; Lee et al., 2017; Polisena et al., 2009; Su et 
al., 2016; Suksombom et al., 2014; Zhai et al., 2014).  All but one of the studies measured the 
clinical outcome of glycemic control (Chamany et al., 2015; Crowley et al., 2016; Egede et al., 
2017; Faruque et al., 2017; Hansen et al., 2017; Jeong et al., 2018; Kempf et al., 2017; Lee at al., 
2017; Liu et al., 2016; Odnoletkova et al., 2016; Polisena et al., 2009; Rasmussen et al., 2015; 
Sood et al., 2018; Stone et al., 2010; Su et al., 2016; Suksombom et al., 2014; Wu et al., 2010; 
Zhai et al., 2014) as measured by improvement from baseline hemoglobin A1C within varying 
time frames, and the majority compared telemedicine to usual care or as a supplement to usual 
care.   
 Within the scope of this literature search seven systematic reviews and meta-analyses 
were located.  According to Fineout-Overholt and Melnyk (2005) these articles provide generally 
strong to moderate levels of evidence (Faruque et al., 2017; Lee at al., 2017; Polisena et al., 
2009; Su et al., 2016; Wu et al., 2010; Zhai et al., 2014).  Suksombom et al. (2014) was graded 
as weak on the Rapid Critical Appraisal Checklist due to only reviewing five small population 
RCT’s, of which two had a high risk of bias.  Eleven randomized controlled trials were also 
evaluated (Chamany et al., 2015; Crowley et al., 2016; Egede et al., 2017; Hansen et al., 2017; 
Jeong et al., 2018; Kempf et al., 2017; Odnoletkova et al., 2016; Rasmussen et al., 2015; Sood et 
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al., 2018; Stone et al., 2010; and Trief et al., 2013) providing further moderate to strong level of 
evidence (Fineout-Overholt & Melnyk, 2005).  A single cohort trial was included by Liu et al 
(2016) because it specifically dealt with nurse practitioners providing telemedicine intervention.  
The VA/DOD Clinical Practice Guideline for the Management of Type 2 Diabetes Mellitus 
(2017) in Primary Care was also included in the review and considered moderate to strong 
evidence.   
 Overall, based on the Rapid Critical Appraisal Checklist (Fineout-Overholt & Melnyk, 
2005), sixteen of the reviewed studies were assessed as providing moderate to strong evidence, 
and the rest were considered weak evidence.  Significant limitations in the majority of the studies 
(particularly systematic reviews) was heterogeneity within the studies, the lack of blinding to 
treatment assignments which could have led to Hawthorne effects/bias, the variation of time 
frames within each study, and the varying modalities and types of health professionals 
conducting interventions within each study.  
Synthesis.  The majority (n = 12) of the reviewed literature reported that telemedicine 
resulted in a statistically significant decrease in A1C (Chamany et al., 2015; Crowley et al., 
2016; Faruque et al., 2017; Hansen et al., 2017; Kempf et al., 2017, Lee at al., 2017; 
Odnoletkova et al., 2016; Rasmussen et al., 2015; Stone et al., 2010; Su at al., 2016; Wu et al., 
2010; Zhai et al., 2014).  Four of the studies showed no clinically or statistically significant 
difference (Egede et al., 2017; Jeong et al., 2018; Liu et al., 2017; Sood et al., 2018; Suksombom 
et al., 2014), and one study measured improvement in self-care which was then correlated with 
improvement in A1C (Trief et al., 2013).  Polisena et al. (2009) reported mixed results.    
 Theme I: Modalities.  One of the key themes of these studies was assessing the impact 
of specific telemedicine modalities on glycemic control, given the broad variety of telemedicine 
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modalities available.  The impact of specific telemedicine modalities was tested in a number of 
the studies, which is of relevance to this project because only telephonic telemedicine was 
available in the clinic where the project was conducted.   
 Chamany et al. (2015), Crowley et al. (2016), Egede et al. (2017), Kempf et al. (2017), 
Odnoletkova et al. (2016), Stone et al. (2010), Suksombom et al. (2014), and Wu et al. (2010) 
looked specifically at telephonic interventions.  Of these eight articles, only one did not show a 
significant improvement in A1C (Chamany et al., 2015; Crowley et al., 2016; Egede et al., 2017; 
Kempf et al., 2017; Odnoletkova et al., 2016; Stone et al., 2010; Wu et al., 2010), while one did 
not show statistically significant differences  (Suksombom et al., 2014).  Suksombom et al. was 
the only systematic review to only assess telephonic interventions and the authors reviewed five 
small RCT’s and the overall quality of this review was rated as weak given potential bias and 
poor discussion of the statistics analyzed.   
 Other systematic reviews and studies used several different modalities such as telephonic, 
video conferencing, messaging and telemonitoring (Faruque et al., 2017; Lee at al., 2017; 
Odnoletkova et al., 2016; Polisena et al., 2009; Su et al., 2016; and Zhai et al., 2014) and the 
authors reported statistically significant improvements in glycemic control.  Studies that tested 
only video conferencing were also evaluated (Hansen et al., 2017; Liu et al., 2016; Jeong et al., 
2018 & Rasmussen et al., 2015) and demonstrated mixed results.   Liu et al. (2017) and Jeong et 
al. (2018) showed no statistically significant difference, while Hansen et al. (2017) and 
Rasmussen et al. (2015) showed a significant decrease in A1C.  The overall evidence indicates 
that different types of interventions as well as combined intervention protocols can provide 
improved glycemic outcomes. 
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 Theme II: Provider type.  The type of providers giving the telemedicine intervention 
varied greatly between studies.  Some of the studies utilized nurses or nurse case managers, 
while some utilized trained health coaches, and still others utilized physicians or nurse 
practitioners.  Studies utilizing either providers alone (physician, nurse practitioner) or nurses 
working with providers to provide medication management and treatment recommendations 
were reported by Crowley et al. (2016), Jeong et al. (2018), Liu et al. (2016), Rasmussen et al. 
(2015), Sood et al. (2018); Stone et al. (2010).   Studies utilizing nurses as educators or case 
managers were also common (Faruque et al., 2017; Hansen et al., 2017;  Lee at al., 2017;  
Odnoletkova et al., 2016 and Trief et al., 2013).  Except for the Liu et al. and Jeong et al. studies, 
all showed improvements in glycemic control.   Liu et al. (2016) demonstrated no statistical 
difference between in person and telemedicine visits.  Jeong et al. (2018) showed significant 
reductions in A1C in all three arms, but there was no statistically significant difference amongst 
the groups.   Several of the systematic reviews did not differentiate the effect of different 
provider types.  Of the three studies that utilized health coaches or health educators (Chamany et 
al., 2015; Egede et al., 2017; Kempf et al., 2017) the results were mixed with two studies 
showing improvement and the one remaining study showing no significant difference in 
outcomes.  Further research would be needed to determine if the lack of significance was due to 
the intervention or the type of provider implementing the intervention. 
 Theme III.  Intervention.  The final key theme is what kind of telemedicine 
interventions had the greatest impact on outcomes.  This was particularly difficult to narrow 
down in the literature because many of the studies used multiple interventions including health 
coaching, disease self-management education, telemonitoring of key measurements such as 
blood sugar, medication management and titration, nutrition education, goal setting and direct 
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interface with clinical providers.  Not every study provided specific details of the intervention 
protocols.  The synthesis of the literature indicated that combined intervention protocols i.e. 
utilizing multiple different interventions via telemedicine led to improved glycemic outcomes 
demonstrated by reductions in A1C.  Best practices of these studies included frequent direct 
contact with patients and providing reinforcement of diabetic self-management skills.   
Limitations 
 Several limitations were noted in this literature review.  The UAA library does not have 
access to EMBASE which could have been another source of studies to support this topic, 
although several systematic reviews accessed studies published in EMBASE.   
 Within the studies and systematic reviews there was a significant amount of 
heterogeneity of the modalities of telemedicine used, the settings and populations studied, and 
the types of providers performing interventions.  There was also heterogeneity within the types 
of interventions themselves, while most included several aspects including diabetes self-
management education, self-care review, and medication management in the provider driven 
interventions.  This made it difficult to isolate exactly which intervention or modality was the 
most effective, however when taken as a whole the use of several combined modalities (i.e. 
protocols involving multiple intervention modalities) appeared to be more effective at improving 
glycemic control.  
Conclusion 
 A review of the literature was conducted that provided sufficient evidence supporting the 
use of telemedicine modalities to improve glycemic outcomes and self-care in patients with 
diabetes.  This review included higher level of evidence including systematic reviews, meta-
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analyses, and RCT’s.  Although there were limitations, several key themes emerged in the 
literature that provided evidence to support this project. 
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Chapter 3: Organizational Framework 
 Havelock’s Change Theory (Havelock, 1973) provides a systematic process for 
developing, implementing, and sustaining change.  Havelock described change as “any specific 
alteration in the status quo” of an organization (p. 4) and his model for change allows the user to 
assess the viewpoint of both the change agent implementing the change, as well as those who the 
change will impact.  Understanding these varying viewpoints allows the change agent to identify 
potential barriers and gain buy-in from stakeholders, which is key given that resistance is 
common to any change in the status quo.  Havelock discussed the stages of change in planned 
innovation in his model, and although it was originally used as an organizational framework for 
education, it has been applied to nursing as well (Udod & Wagner, 2018).  Medical providers are 
often very ingrained in their practices so it is important to be able to demonstrate in a logical 
manner the value and feasibility of any new process, and garner buy-in so that the providers 
themselves can lead the impetus for change.   
 Havelock (1973) discussed the difference between reflexive change versus planned 
change as another key aspect to support his theory.  Within the military, and medicine in general, 
reflexive change is often the norm, and many times the change either does not address the root 
cause of the problem or it can’t be sustained due to poor staff buy in or poorly planned 
implementation.  Havelock’s Theory imparts the importance of using a systematic approach 
which also integrates well into evidence-based practice, ensuring changes are made in a way that 
can be sustained within the organizational culture.   
Evidence-Based Practice Model 
 Havelock’s Theory of Change (1973) was originally developed and expanded based on 
Lewin’s Theory of Change (1951).  Havelock designed his theory to provide an organizational 
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framework for creating reforms within organizations.  His theory consists of a six stage process 
that allows the change agent to progress through organizational change in a systematic and 
sequential manner (Havelock, 1973).   The six phases of Havelock’s Theory are Relate, 
Examine, Acquire, Try, Extend, and Renew (Havelock, 1973).   
 Havelock’s theory (1973) was designed to be used by the people working within the 
organization, often with a bottom-up approach, which suits this project well as it is provider 
driven, not leadership driven.  He describes how change agents can organize their work to be 
successful and he provided case studies throughout each step that include examples of practical 
ways to implement change.  Havelock described four ways a person can act as a change agent – a 
catalyst, a solution giver, a process helper, and a resource linker.  All of these aspects could be 
used within the six steps of Havelock’s model (Figure 1).  Havelock recommended starting the 
change process by diagramming the organization as a system to understand how it works 
(Appendix C), and then identifying potential stakeholder allies and involving them early.  The 
change agent should seek to become an expert on their process and analyze the concerns of 
adversaries in detail so that all points of view can be understood.  These processes facilitate the 
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Figure 1. Adapted Illustration of Havelock’s Theory of Change (1973) 
 
Step One: Relate.  The first and possibly most important step in Havelock’s Theory 
(1973), “Relate”, is the phase of determining that a need for change exists and then building 
relationships with clients or stakeholders.  Havelock stressed that for a change agent to be 
successful, they must develop good relationships and involve key stakeholders early in the 
process.  Havelock identified the importance of identifying organizational norms, leaders, 
influencers, and gatekeepers.  Havelock encouraged frequent conversations, involvement, and 
inviting opposing views to the table during this step.  The priority at this stage is to “know your 
innovation inside and out” (Havelock, 1973, p. xi) and creating alliances to allow for success. 
 This stage was key in developing and implementing this evidence-based project.  The 
need was already demonstrated in clinic metrics showing a significant number of diabetics in the 
clinic failed to meet A1C goals despite all usual care practices (Carepoint, 2019).  Providers are 
tracked by leadership on whether or not they meet these quality metrics as usual practice, and 
both leadership and providers were vested in demonstrating improved outcomes.  As the Family 
DocuSign Envelope ID: 28A56752-5014-41FF-AF51-8729673AFFC0
TELEMEDICINE AND DIABETES  35 
 
Health Clinic transitioned to Defense Health Agency leadership, there was even more impetus to 
demonstrate effective outcomes-based processes in the clinic.  Key stakeholders included 
providers, nurses, and healthcare staff in the Family Medicine Clinic who implemented this 
process change, Family Medicine Clinic and 673rd Medical Group Executive Leadership who 
provided approval, and the patients themselves who participated in this enhanced follow-up.   
 Havelock’s (1973) first stage involves assessing readiness for change in organizations 
and he provided examples of how this process could work in various case studies.  In this stage,  
it was important to assess the motivation/knowledge of EBP principles in the clinic.  As a 
provider in this clinic, the project coordinator already had an established working relationship 
with providers, staff and clinic leadership.  At the time of this project, the Family Health Clinic 
was already utilizing limited telemedicine modalities for certain conditions, and providers and 
patients generally viewed this as a positive service.  In addition, the clinic and leadership culture 
was already very proactive in accepting and implementing evidence-based medicine as 
evidenced by previous performance improvement projects that had been successful.  This project 
involved additional provider time, although the follow-up visits occurred within normally 
templated visits during the duty day.  Providers were educated on the time and resources 
involved ahead of implementation and given opportunities to develop a process that fit well with 
current practices. 
 As this project progressed, engagement and education occurred for the providers and 
clinic teams during provider and staff meetings, as well as engaging with the unit practice 
council to garner interest and support.  The unit practice council had been significantly involved 
in several evidence-based practice changes previously and their recommendations carried 
significant influence with leadership.  The medical director, providers, and clinic leadership were 
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engaged early in project plans and were consistently supportive.  The Air Force Center for 
Evidence Based Practice reviewed this project concept and ensured it remained within the 
guidelines of the Air Force for implementing a practice change of this nature.  The 
operationalization of this project also involved a clear process for helping patients understand the 
potential benefits and garnering their engagement to participate in a more intensive follow-up 
regimen.  Making this project provider-driven ensured that patients had continuity with their 
primary care provider team for these follow-ups. 
 Step Two: Examine.  During the “Examine” stage, the problem is formally diagnosed or 
identified (Havelock, 1973).  As mentioned above, a significant percentage of Family Health 
Clinic patients fail to meet A1C goals, likely due to a number of factors (Carepoint, 2019).  One 
of the major factors has been patients not returning to the clinic for recommended follow-up 
appointments.  This is likely multifactorial, however providing an alternate venue for follow-up 
was thought to potentially eliminate some barriers.  The VA/DOD Clinical Practice Guidelines 
for the Management of Type 2 Diabetes Mellitus in Primary Care (2017) recommends that 
telemedicine modalities be utilized in improving diabetic outcomes; however, this 
recommendation had not been implemented in the clinic.  The CPG provided evidence and 
recommendations to support the use of telemedicine to improve outcomes.  This project 
addressed the lack of implementation of the CPG recommendations.  
 Step Three: Acquire.  In the third phase, “Acquire”, resources are gathered, and relevant 
information is used to develop solutions (Havelock, 1973).  In this stage the change agent needs 
to identify what resources are needed and obtain them.  The literature review provided the 
evidence and direction for the design and implementation of the project.  A protocol and 
instrument were developed based on best evidence to provide standardization for the providers 
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during the telemedicine encounters.   No additional equipment was needed for this project.  
Training was developed as mentioned above for those involved in the implementation.  Health 
Care Integrators and the Carepoint database were used to identify patients who meet inclusion 
criteria for the project.   
 Step Four: Try.  “Try” is the step of choosing the solution and implementing the process 
change (Havelock, 1973).  In this stage the change agent and Family Health Clinic providers 
made decisions on implementation.  The guiding principle was to reshape solutions to meet the 
specific needs of the client (Havelock, 1973).  In this stage the actual change was implemented.   
 Once agreement amongst the stakeholders was reached on the best course for 
implementing this project, employment commenced.  During the implementation phase close 
contact was maintained with all of the participating providers and teams to identify any barriers 
that developed so they could be addressed immediately.  Obstacles and barriers were 
documented as the project progressed.  The process itself was designed in a way that made it 
sustainable and integrated well into workflows already used in the clinic, ensuring providers did 
not have to invest significant additional clinical time into these visits.  Visits were scheduled 
onto the providers existing schedule templates, in designated follow-up (SPEC) appointments.  
A1C was monitored as the primary clinical measure of the project, and patients were requested to 
obtain the labs prior to the start of the project as deemed necessary by their PCM, and at the end 
of the 3 month project.   
 Step Five: Extend.  “Extend” involves sharing and disseminating findings and 
highlighting outcomes to all involved in order to gain acceptance for the change (Havelock, 
1973).  In this stage the change agent should describe, discuss, develop interest, evaluate, and 
formally adopt the changes made (Havelock, 1973).  It is important to maintain communication 
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with all stakeholders and provide education and a support structure for those implementing the 
change.  In this stage data was obtained and evaluated, acceptability was assessed with provider 
input, and barriers were identified and ameliorated when possible.  Findings were disseminated 
to providers, staff and leadership including relevant statistical findings. 
 Step Six: Renew.  The final phase, “Renew”, involves sustaining the process, creating 
self-renewal, and once the process is established the change agent can separate from the process 
(Havelock, 1973).  Havelock (1973) described this stage as the internal capability to maintain the 
innovation.  In this stage it is important again to assess stakeholder input, client perceptions, and 
any resistance to maintaining the change and provide ongoing feedback and data to the teams.  
Monitoring for continued use of the practice change is also part of this stage.  This stage is 
continuous after the completion of the three month project.  The formal conclusion of this project 
coincided with the project coordinator’s military move to a different location.  However, regular 
communication continues at the time of this writing between the project coordinator and the 
Family Health Clinic team to discuss continued sustainment of the program.   
Conclusion 
 Selecting an appropriate change theory to provide a project framework is an essential part 
of a DNP project.  Havelock’s Theory provided an excellent framework for this project.  This 
theory has six steps that successfully guided the project development through the planning, 
implementation, data analysis, and dissemination stages.   
  
DocuSign Envelope ID: 28A56752-5014-41FF-AF51-8729673AFFC0
TELEMEDICINE AND DIABETES  39 
 
Chapter 4: Design and Methods 
Design 
This quality improvement project used a pre-test post-test design with laboratory and 
survey data to measure A1C, diabetes self-care management (DSMQ questionnaire), and a post-
test only provider satisfaction survey.  Quantitative data was used for analysis.  The primary 
metric of interest was the change in mean hemoglobin A1C over three months for the patients 
who participated in the telemedicine intervention program.  Secondary metrics included pre- and 
post- diabetes self-care scores and provider satisfaction scores at the end of the project.  
Descriptive statistics included demographic data such as age, race, and gender of the patients.  
The total number of patient visits was also tracked. 
Setting and Population  
 This project was implemented at the Joint Base Elmendorf-Richardson Family Health 
Clinic which is part of the 673rd Medical Group located in Anchorage, AK.  The 673rd Medical 
Group is a United States Air Force/Department of Defense Military Treatment Facility serving 
active duty military personnel, their family members, as well as retired military personnel and 
their dependents.  The clinic treats all ages from infants to geriatrics.  Approximately 25% of the 
patients served are active duty military, with the remainder being dependents or retirees.  The 
clinic itself serves a large region of Alaska.  The entire medical group has 1,856 patients enrolled 
with a diagnosis of diabetes as of June 2019, of which 264 had a most recent A1C of greater than 
or equal to 8.0 (Carepoint, 2019).  The clinic has 19 providers (13 beneficiary providers and 6 
active duty providers), including nurse practitioners, physicians, and physician assistants, each 
managing an empanelment of approximately 1,250 patients.   
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 This project was implemented for adult patients enrolled in the clinic with a diagnosis of 
Type 2 Diabetes and with an A1C at or above 8.0.   Inclusion criteria for this project was adult 
patients (age 18 years or older) with Type 2 diabetes and most recent A1C greater than or equal 
to 8.0.  Exclusion criteria included patients managed by an off base provider for diabetes 
(endocrinology, VA, or off base civilian primary care), patients not seen in the clinic within 12 
months for a provider visit, patients unable or unwilling to utilize phone follow-up (lack of 
access, not comfortable doing virtual visits), patients with end of life care or terminal illness, and 
patients lacking cognitive or communication skills (language barriers, dementia) to participate in 
phone visits.  The intervention was offered to all eligible patients empaneled to the participating 
providers. 
  A critical review of the evidence focused on diabetes and telemedicine found that 
glycemic outcomes could be improved using telemedicine modalities.  This clinical quality 
improvement project was based on components of several of the studies that demonstrated 
improvement in glycemic outcomes, and as such was not conducted for the purpose of research.   
This project is not generalizable beyond the participating patients in the 673rd Medical Group 
Family Health Clinic, however the data from this project could be utilized to inform program 
development in other similar clinics.  Patient agreement was sought for inclusion in the project, 
however declining participation did not impact a patient’s ability to receive usual care; all 
interventions provided in this project were in addition to the usual standard care available.   This 
project was deemed “Not Human Subjects Research” by the University of Alaska IRB.  In 
addition, this project was approved by the 673rd Medical Group Commander and executive 
leadership team, and through the Air Force Human Research Protection Office.     
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 Key stakeholders included the primary care providers, clinic and hospital leadership, and 
care team staff (registered nurses and medical technicians).  A total of 13 providers were asked 
to conduct the virtual telephonic follow-up visits.  They were involved in the planning process, 
with education provided to them prior to starting the intervention phase of the project.  Training 
provided consisted of an overview of the project, the evidence supporting the project, and the use 
of the instrument developed for this project.  Leadership was involved for oversight and planning 
of the project as well as to ensure support.  Care team staff assisted the providers as needed in 
pre-screening of the patients for the telephone visits and were also educated on the program. 
  The project was cost neutral with the primary resource being provider time and 
commitment.  Laboratory testing was already occurring at regularly scheduled intervals and 
therefore did not incur additional costs to the patient or clinic.  Telephonic follow-up was used, 
and all providers in the clinic had phone and computer access.   Education for providers and staff 
was conducted during regular duty hours, requiring no additional time investment.  
Documentation was the same as per a typical visit in the Armed Forces Health Longitudinal 
Application (AHLTA) electronic health record (EHR).  An instrument (Appendix E) was given 
to the providers to guide the telephone follow-up intervention.  The virtual visits were booked 
during the normal clinic day as a regularly scheduled SPEC appointment and scheduling the 
follow-up visits were the responsibility of each provider team.  The project was designed in such 
a way that the visits could be accomplished within a short 10 to 15 minute telephone visit.  Key 
facilitators included establishing provider and leadership buy in early and continuously, 
providing education to ensure consistency in implementation, and monitoring the 
implementation frequently to ensure providers stayed on track with follow ups and to address 
any issues that developed. 
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Intervention/Practice Change 
 This project utilized a provider implemented intense telephonic follow-up intervention.  
The Military Health System Carepoint database was utilized to identify patients on each provider 
team that had a most recent A1C of 8.0 or greater within the past year.  Each patient on the list 
was reviewed against inclusion and exclusion criteria, and the names of those meeting criteria 
based on initial review were given to each participating provider.  Participating providers also 
reviewed each patient on their list to ensure appropriateness for this intervention and final 
discretion was up to the provider to eliminate any patients they felt were not appropriate for this 
intervention.   
 The telephonic intervention included several components including medication 
management/titration, diabetes self-management education such as self-monitoring blood sugar, 
healthy lifestyle change counseling including healthy diet and exercise, and referral to ancillary 
resources such as nutrition or pharmacist if indicated.  These key elements were included in the 
majority of telemedicine studies reviewed in the literature that demonstrated improved glycemic 
outcomes (Crowley et al., 2016; Hansen et al., 2017; Lee et al., 2017; Rasmussen et al., 2015; 
Sood et al., 2018; Su et al., 2016) as well as the VA/DOD Clinical Practice Guidelines (2017).   
 A diabetes screening instrument developed by Gervera and Graves (2015) for the VA 
telemedicine program utilized the VA/DOD Clinical Practice Guidelines and was modified for 
use in this project to reflect the DOD population and ensure compatibility with current VA/DOD 
CPG.  There are no validity/reliability measures associated with this instrument.  The tool was 
used to ensure the telephone visits met the key elements described above for each patient in order 
to maintain consistency.  The author of the tool, Kelly Gervera DNP, RN gave her permission for 
the instrument to be modified and used in this project.  A copy of the permission to modify is 
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included in Appendix D, and the modified tool is available in Appendix E.  The decision was 
made to modify this tool for the project, because it was developed based on VA/DOD evidence 
based guidelines for diabetes management, and the project coordinator was unable to locate a 
tool in the literature that specifically matched the goals for this project.   This tool could not be 
used in its current form because it included items not related to glycemic control and had VA 
specific items not relevant to this project.  However, the core components of the tool related well 
with the key items included in this project.   
 Providers performed telephonic follow-up calls to the identified patients during scheduled 
appointments in the implementation phase every two to three weeks for a three month period. 
The virtual visits lasted approximately ten minutes and covered items such as patients’ home 
glucose monitoring results, medication compliance, setting goals for lifestyle changes, providing 
targeted education on diet and exercise, and inputting referrals for additional services such as 
dietician, disease educator, and clinical pharmacist.  The initial DSMQ questionnaires were 
provided to the providers as a clinical instrument to assist them in setting goals for the virtual 
visits.  The providers utilized the telemedicine program instrument described above as a 
guideline to keep the visits on track and documented the encounters in AHLTA.  At the end of 
the three month implementation period data were analyzed and presented to stakeholders.   
Measures 
 In order to measure glycemic outcomes in this project, the mean change in A1C for 
patients from baseline to end of intervention (pre-post measurements) were compared.  Patients 
had their labs drawn at the JBER lab for the pre-test and post-test measures of A1C, and all 
A1C’s were measured in the same lab to ensure consistency.  Secondary outcome measures 
included a brief Likert-style survey given to participating providers regarding their satisfaction 
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with the telemedicine intervention (measured by a post-survey).   The provider survey was based 
loosely on content found in a survey created by Tudiver et al. (2007) to measure provider 
satisfaction with the ground-breaking IDEATeL project.  Diabetes self-care scores were assessed 
pre- and post- intervention using the previously validated Diabetes Self-Management 
Questionnaire (DSMQ) (Appendix G) (Schmitt, 2013) to assess for change in scores.  Permission 
was obtained to use the DSMQ in this project (Appendix J).  The DSMQ is a 16 item 
questionnaire that measures the patient’s self-care activity for the previous eight weeks on a four-
point Likert scale.  It contains four sub-scales that assess glucose management, dietary control, 
physical activity, and health care utilization.  The higher the score on the DSMQ, the higher the 
patient’s rating of self-care (Schmitt, 2016).  These surveys were administered by the project 
coordinator via phone and scored as detailed by Schmitt et al. (2016).  The DSMQ instrument 
has been shown to be both reliable and valid with good internal consistency and comparable to 
other validated diabetes self-care instruments, for patients with Type 2 diabetes (Bukhsh et al., 
2017; Schmitt et al., 2013; Schmitt et al., 2016).  It is scored using a total sum score for the 
whole instrument and broken down into the four subscales – glucose management, diet/nutrition, 
exercise/physical activity, and healthcare. 
Data Collection 
 Establishing a structured process for planning, implementation, and data collection is 
essential to any quality improvement project.  Project planning and oversight was managed by 
the project coordinator who maintained close communication with the clinic medical director and 
key stakeholders.  A secure excel spreadsheet was utilized to track all data which was maintained 
on a secure CAC (ID) card enabled government computer that only the project coordinator could 
access.  The pre-intervention phase began with proposal approval.  Once the proposal was 
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formally approved, the project coordinator worked within the clinic to educate key stakeholders 
on the project concept and goals including conducting meetings with clinic providers, the clinic 
leadership team and Unit Practice Council, Medical Group Chief Nurse and Command Staff, and 
individual teams to build support and obtain approval for project implementation while assessing 
readiness and educational needs from all the key players.   
 Training to orient staff and medical providers on the project implementation plan were 
conducted.  This training identified each person’s role in the project and ensured intervention and 
follow-up timeframes for each virtual visit.  The training was started as formal in-person training 
led by the project coordinator during scheduled medical provider meetings and staff meetings but 
transitioned with short notice to virtual and smaller group training due to COVID-19 safety 
precautions.  Key elements of training included use of the protocol instrument, timing of visits, 
content of visits, patient protection/privacy, and documentation in the medical record.   
 Pre-intervention data collection.  Patient and provider recruitment was the 
responsibility of the project coordinator.  Providers in the Family Health Clinic were encouraged, 
but not required to participate.  The number of patients who were offered this intervention but 
declined to participate was tracked.  Once provider participation was determined, eligible 
patients on those provider teams were identified based on the Carepoint database and criteria 
discussed previously.  The Health Care Integrator scrubbed the list to remove patients who had 
not been seen in clinic in greater than 12 months, and those known to have primary care off base.  
Eligible patients were then contacted by phone by the project coordinator and educated on the 
voluntary nature of the project, and the project details including time frame for follow-up visits.  
If patients agreed to participate, they were scheduled for an initial phone appointment with their 
PCM provider and an initial A1C lab was ordered by their PCM if clinically indicated.  The 
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DSMQ questionnaire was completed with the patient over the phone by the project coordinator.  
Descriptive data including age, race, and gender were obtained for each participant.    
 Intervention.  Project oversight was managed by the project coordinator and in close 
consultation with the clinic medical director.  The project coordinator interacted with each 
participating provider and their medical technicians at least weekly to ensure continued project 
success.   
 Providers utilized the instrument developed to guide telemedicine visits during this 
project, with the premise that providers would tailor each visit to reflect specific 
patient/outcomes goals.  Providers conducted telephonic visits with each participant every two to 
three weeks at scheduled times based on provider schedule availability utilizing designated 
follow-up (SPEC) appointments.  The instrument developed provided a guideline for goal setting 
with patients at each visit, and basic education and diabetes self-management topics to be 
discussed.  Providers were also able to provide medication management/titration if indicated.  
All visits were documented in the medical record as per usual practice. 
 Post-intervention data collection.  At the end of the 3 month implementation phase, 
providers ordered a post-A1C lab on each patient.  In addition, the DSMQ questionnaire was re-
administered by the project coordinator.   The overall DSMQ total sum score and sub-scales 
were assessed.  At this time providers who participated were also surveyed with an anonymous 
and voluntary paper survey to identify their level of satisfaction with the telemedicine project.  
This survey was conducted after duty hours and strictly voluntary to meet the requirements of the 
Air Force Survey Office.  Data was then analyzed including mean change with standard 
deviation in A1C scores from pre- and post- intervention and mean change in DSMQ 
questionnaire scores from pre- and post- intervention with standard deviations.  These items were 
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assessed to demonstrate effects on glycemic control and determine change in self-care status.  
Appropriate statistical analysis was then performed, including paired t-tests and Wilcoxon signed 
ranks tests.  Once statistical analysis was completed, information was disseminated to all key 
stakeholders.  
Program Evaluation and Data Analysis   
 Demographic data was obtained on all patient participants.  Documentation of obstacles 
and barriers was discussed.  The effectiveness of the project was evaluated by assessing the 
change in hemoglobin A1C over three months, change in scores on the DSMQ questionnaire, 
and provider satisfaction.   
 Sample.  Demographic data was collected from participants including age, race, and 
gender.  Gender and race were measured at the nominal level (male/female; White, Black, 
Hispanic, Asian, Other).  Age was collected at the interval level (age in years).  Descriptive 
statistics were utilized to describe the patients in this project.  Nominal data was presented as 
percentages (i.e. % male, % female).  Interval data was presented by mean and range and 
standard deviation.   
 Outcome measures included change in mean A1C difference scores, change in DSMQ 
scores, and post intervention provider satisfaction.  Data was obtained from pre- and post- 
intervention A1C lab results available in the Carepoint database, DSMQ questionnaire scores 
pre- and post- intervention, and mean of provider satisfaction scores using a Likert-style 
questionnaire.   
 A1C is an interval/ratio level of measurement and means were calculated at pre- and 
post- intervention showing mean change with standard deviations reported.  A1C and DSMQ 
measures were analyzed using either a paired t-test or the nonparametric alternative Wilcoxon 
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Signed Ranks test.  Provider satisfaction was obtained from a Likert-style survey with means and 
standard deviations reported.   
Cost-Benefit Analysis and Budget 
 This project did not incur any financial costs.  No additional monetary expenses are 
anticipated in the future.  SPEC telephone visits are billable in Tricare as per current practice.  
Training was developed and conducted by the project coordinator and conducted at regularly 
scheduled intervals during the project.  Provider and staff time was the primary cost.  Individual 
provider time was estimated at five hours per provider for project duration, based on a 12 week 
implementation phase with virtual visits conducted on average of every three weeks for a total of 
four to five visits, each lasting estimated 15 minutes = 75 minutes total in direct patient contact, 
with an additional 10 minutes per patient for charting and administrative aspects = 50 minutes.  
Provider time for training included one hour for initial training, with intermittent informal 
follow-up discussions and virtual presentations estimated at one hour per provider.  Medical 
technicians incurred a limited time commitment for any needed pre-screenings for each visit, 
estimated at one to two hours during project duration.  Nurses were not directly involved in the 
virtual visits and were not expected to incur additional time.  No additional equipment or 
services were anticipated for this project.   Table I-1 (Appendix I) details cost versus benefit 
analysis for this project. 
Timeline 
 Table I-2 (Appendix I) summarizes the timeline for this project.  In Spring 2020, proposal 
defenses and approval occurred, followed by IRB submission and not-HSR determination.  Once 
Medical Group approval was obtained, provider and staff education was conducted, along with 
provider recruitment.  All preparations including stakeholder education, ensuring buy in, and 
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preparations occurred during this time frame.  The implementation phase occurred over a three 
month period from April 2020 to July 2020.  Data analysis and outcomes measurement occurred 
in September 2020 and October 2020 and the dissemination of findings occurred in October and 
November 2020, which concluded in the project defense in November 2020.  Further 
dissemination including planning for formal publishing and poster presentation of these findings 
will continue into 2021.   
Ethical Considerations/Protection of Human Subjects 
 No significant risks to human subjects were anticipated in this study.  The risk of data 
breach was minimized using appropriate privacy protections.  The risk to patients participating in 
this project was no different from the risks of patients receiving standard care.  All relevant DOD 
Clinical Practice Guidelines were followed.  This clinical project delivered care according to 
current guidelines using telemedicine.  All patients who met criteria and could be contacted by 
phone were asked if they would like to participate.  Potential benefits to subjects included 
enhanced/more frequent follow-up, more targeted goal setting with follow-up, and increased 
access to providers versus only usual care, and potential improvement in glycemic control and 
diabetes self-management.  No usual treatment was withheld from patients.  Provider data only 
included the post survey, which was anonymous.  Patient collected data included demographics 
such as age, gender, and race, with outcome data such as A1C and DSMQ scores being tracked.  
Patient data was completely de-identified in reporting findings and any study documents were 
stored on a CAC/password protected computer that only the project coordinator had access to.   
 The University of Alaska Anchorage Institutional Internal Review Board (IRB) and U.S. 
Air Force non-HSR determinations were obtained prior to initiating the DNP Project.  All 
participants were protected by the Health Insurance Portability and Accountability Act of 1996 
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(HIPAA) which protects the privacy of patients’ health information, and the Medical Group 
HIPAA Privacy Officer reviewed and approved the project.  Additionally, the DNP student and 
practice personnel who conducted this project followed all appropriate DOD and accepted 
standards of care during this project.  The project coordinator and committee also maintained 
appropriate CITI training requirements.   
Conclusion 
 The literature supports the use of telemedicine to improve glycemic outcomes in patients 
with Type 2 Diabetes.  This DNP project clinical quality improvement intervention was based on 
best practices and standards of care found in the literature.  The project was conducted in an 
organized and structured manner, while ensuring human subjects protections, as detailed in this 
plan with the goal of improving diabetic outcomes. 
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Chapter 5: Implementation 
 This chapter discusses the implementation of the Diabetes Telemedicine project in the 
Family Health Clinic at the 673rd Medical Group.  Project implementation began ahead of 
schedule in early April 2020 and continued through the end of July 2020.  This chapter discusses 
the implementation process and procedures, barriers, and unexpected challenges that arose 
related to the SARS-CoV-2 Coronavirus (COVID-19) national public health emergency. 
Implementation Process 
 Upon completion and approval of the DNP Proposal Defense in February 2020, 
University of Alaska Anchorage Institutional Review Board (IRB) Human Subject Research 
Self-Determination and subsequent IRB Human Subjects Research Determination were obtained 
and the project was deemed “Not Human Subjects Research.”  Approval was obtained from the 
entire executive leadership team at the 673rd Medical Group including the Family Health Clinic 
Flight Commander, Flight Chief and Medical Director; 673rd Medical Operations Squadron 
Commander and Superintendent; 673rd Medical Group Chief Nurse, Chief of Medical Staff, 
Quality Improvement Director, HIPAA Privacy Officer, Deputy Commander, and Commander.  
The Air Force Survey Office was consulted and gave approval to utilize the DSMQ 
questionnaire as a “clinical instrument” and advised that the provider survey must be anonymous 
and conducted after hours not using any government time or materials to be in compliance with 
Air Force regulations.  Once the needed Medical Group approvals were received, a packet 
including the project protocol and IRB review paperwork was compiled and submitted to the Air 
Force Human Subjects Research Protection Office at Air Force Medical Headquarters, where the 
project proposal was appraised by the Human Research Protection Official (HRPO).  Various 
concerns and clarifications were addressed, particularly ensuring the ability of the individual 
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providers to diverge from the protocol when they felt clinically indicated.  The project received 
final Air Force support to proceed in the end of March 2020. 
 During the IRB and Air Force review process, meetings with key stakeholders in the 
clinic were held in February and March 2020.  The project coordinator met individually with all 
Flight Leadership, individual clinic providers, diabetes management nurses, the clinical 
pharmacist, the health care integrator, administrative support staff, and other team members to 
discuss and address any potential barriers to the project.  The Flight Commander and Medical 
Director and other stakeholders were very supportive of this project, and no significant barriers 
were identified.  The project coordinator also led briefings at the monthly Unit Practice Council 
(UPC) meeting and monthly provider meeting to discuss the project and obtain buy-in from unit 
level change agents.  The project was well-received and supported by the UPC members and 
providers.  
 With final approvals received in March, the formal staff education process was initiated.  
Due to restrictions occurring because of COVID-19, the clinic provider meetings, UPC meetings, 
and staff meetings were cancelled due to social distancing requirements.  This required the 
project coordinator to conduct last minute virtual and small group training sessions for the entire 
clinic.  A PowerPoint educational presentation was developed which provided information on the 
background and evidence base for the project, project purpose and goals, and specific steps for 
implementation and evaluation.  A detailed discussion on the use of the project instrument 
(developed from the instrument created by Gervera & Graves, 2015), VA/DOD CPG, follow-up 
requirements, and use of the DSMQ questionnaire were included.  Relevant resources and 
handouts were provided electronically including a link to the VA/DOD CPG and other diabetes 
management resources from the American Diabetes Association (ADA).  This was mandatory 
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for all clinic providers participating in the project.  Separate and more abridged educational 
information was provided to clinic RN’s, technicians, and support staff as well as key 
stakeholders such as the clinical pharmacist, health care integrator, and disease managers.  After 
the virtual presentations, small socially distanced group meetings were held with each 
participating provider team to allow the opportunity for questions and clarifications.  Once the 
initial onboarding education was completed, providers were given the opportunity to opt in or 
out of the project.  Out of the 13 eligible beneficiary providers in the clinic, 12 opted to 
participate in the project (one new provider assumed a participating providers panel during the 
project).  The only provider not participating cited an upcoming deployment and leave scheduled 
as concerns for possible lack of PCM continuity.   
 In early April, the project coordinator met with the Health Care Integrator, and a database 
report from Carepoint was generated with the names of all the patients in the Family Health 
Clinic with a most recent A1C of 8.0 or greater.  Some of these patients had not had a recent 
A1C in over six months.  This list was cleaned by the HCI to remove patients who no longer 
received primary care in the Family Health Clinic and/or who had not been seen in clinic for 
over a year.  The final list included a total of 75 patients.  Of those 75 patients, eight were 
empaneled to the provider who opted out of the project and those patients were not contacted.  
Data available from the database included the most recent A1C values and basic demographic 
information such as age, sex, and race.  The project coordinator attempted to call all of the 
remaining patients on the list and was able to reach 56 patients.  Patients not reached either did 
not answer after multiple attempts, did not have a working/correct phone number, or did not call 
back when messages were left on their voicemails.  Of the patients reached, 31 met inclusion 
criteria and agreed to enroll in the program, and nine were excluded based on exclusion criteria 
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(most commonly being managed by an off base endocrinology provider).   Eleven patients 
declined to be included in the program, and one was excluded based on PCM judgement as not 
being an appropriate candidate for the telemedicine project due to mental health reasons.     
 Once patients agreed to participate in the project, the project coordinator conducted the 
DSMQ questionnaire over the phone.  Scores were calculated and recorded in an excel 
spreadsheet maintained on a secure CAC protected government computer to which only the 
project coordinator had access to.  Scores were calculated for the total DSMQ summary score 
and for the four subscales which included glucose management, dietary control, physical 
activity, and health care utilization.  The questionnaire results were also scanned into the medical 
record to be available for providers to review and use the information for individualized goal 
setting with their patients.  The patients were then scheduled for a virtual (SPEC) visit with their 
PCM team provider.  
 The first virtual visits began on April 9, 2020 with staggered starting times over the 
following two to three weeks based on when patients could be reached/scheduled.  All providers 
were educated on the follow-up interval goal of every two to three weeks, with a goal of at least 
four to five visits over three months.  Providers had access to the most recent A1C in the medical 
record and ordered updated A1C’s on patients as clinically indicated.    
 During the implementation phase the project coordinator conducted brief weekly virtual 
education (every Wednesday) for the providers including various aspects of diabetes 
management covered in the VA/DOD CPG such as nutrition resources, medication management 
guidelines, exercise guidelines, and motivational interviewing techniques.  The project 
coordinator also reached out via email or in person with each of the participating providers 
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weekly to ensure patients were being scheduled into follow-ups appropriately and address any 
concerns that arose.   
 During the course of the project, four patients were enrolled but never scheduled their 
first appointment after staff made multiple attempts to reach them.  During the project three 
patients had their first visit with the provider but chose not to schedule additional follow-up. 
 Data collection for the project completed at the end of July 2020.  The project coordinator 
contacted all participants and conducted the post-DSMQ questionnaire and A1C data was 
compiled over the next month.  Provider surveys were conducted anonymously during off duty 
hours.  All data was collected by the project coordinator and entered into the appropriate Excel 
spreadsheet. All data was de-identified in reporting to protect patient privacy. 
Barriers/Challenges 
 The greatest barrier to implementation was the multiple levels of approval required 
within the Air Force system.  This required frequent meetings and conversations with multiple 
stakeholders in a variety of different locations and units, as well as the Committee Chair to 
navigate the process.   Fortunately, leadership and the providers in the Family Health Clinic were 
very supportive and agreeable to this project and even the one provider who did not participate 
did so mainly because of his scheduling availability and a pending deployment.  Havelock’s 
Change Theory (1973) proved to be the correct framework by recommending early and continual 
stakeholder engagement which helped streamline the approval process and implementation.   
Impact of COVID-19 on Implementation Plan 
 Due to the COVID-19 National Public Health Emergency, several modifications had to 
be made to this project at the last minute.  Access to the base and clinic became much more 
restrictive in order to reduce risks to patients and staff.   The Defense Health Agency (DHA) 
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allowed expansion of virtual/telephonic visits for the majority of visit types, and many of the 
Family Health Clinic providers began doing solely virtual visits and were assigned to telework 
from home.  Patient volume in the clinic dropped significantly during the months of April, May, 
and June -  attributed to many patients being afraid to come in.  The increased use of 
telemedicine fit extremely well with the concept in this project, and it became even more 
important to offer virtual access to the diabetic patients since in-person clinic appointments were 
extremely limited.   
 The difficult decision was made among the providers participating in the project and the 
project coordinator that an across the board pre-A1C lab in April would not be obtained on every 
patient, due to the increased risk of coming into the hospital if the test wasn’t essential to the 
providers medical decision making.  Patients were assessed on a case by case basis by the PCM 
to determine if they needed an A1C or if the previously recorded A1C and home glucose 
monitoring were sufficient to make treatment decisions.  In reviewing the database results pre-
implementation, approximately half of the patients had an A1C within the past three months, and 
the other half were within the past year.   The same challenges occurred during the timing of 
post-A1C’s in July and August, as many patients were not willing to come into the clinic for 
labs.  This created limitations in A1C data completeness, with eight patients not obtaining a post-
A1C.  
 The COVID-19 crisis also created a number of rapid and sometimes chaotic workflow 
changes within the clinic.  One participating provider had to deploy with three days-notice; 
another was tasked to staff a separate respiratory testing clinic full time and pulled from normal 
duties, and one was briefly tasked to staff an inpatient services unit.  Other providers were 
assigned to fill in for them and fortunately all of the back-filling providers had been trained to 
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participate in the program.  A new provider also joined the clinic towards the end of the study to 
replace one that was transferring out.  Appropriate education was provided in real time for that 
provider to get them oriented.  All of these changes required the project coordinator to interface 
frequently with participating teams and leadership, which was also a challenge since the 
coordinator was working from home during two of the project months.  Fortunately, despite all 
of the fluctuations during the pandemic, most of the providers remained in place throughout the 
project and were able to provide continuity and consistent visits for their patients.  All patients 
who desired participation were able to complete the program.   
Conclusion 
 Despite the challenges presented by the COVID-19 pandemic, this project was able to be 
successfully implemented and all patients who desired participation were able to complete the 
program.  Although there was some expected attrition, it was minimal.  The biggest limitation 
was the lack of consistency in the timing of A1C’s both pre- and post-, however DSMQ and 
provider surveys were obtained as planned. The biggest strength of implementation was having 
supportive stakeholders, participating providers, and flexibility - which is the key to Air Power in 
the Air Force.    
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Chapter 6: Data Analysis and Outcomes 
 Chapter 6 discusses the data analysis and outcomes of the Diabetes Telemedicine Project 
conducted in the Family Health Clinic at the 673rd Medical Group.  Data analysis was conducted 
to determine whether the project demonstrated statistical and/or clinical significance on 
outcomes including glycemic control (measured by mean change in A1C), self-care management 
(measured with the Diabetes Self-Management Questionnaire [DSMQ] instrument), and provider 
satisfaction (measured with the provider satisfaction survey).  This chapter addresses data 
analysis, findings, and limitations.   
Outcome Measures 
 The primary outcome measure of this project was the mean change in pre- and post- 
intervention A1C levels.  Two secondary outcome measures were chosen to evaluate this project.  
The DSMQ questionnaire evaluated mean change in patient reported self-care including 
subscales for dietary control, health care utilization, physical activity, and glucose management.  
Provider satisfaction was measured using a voluntary, anonymous Likert-style survey designed 
specifically for this project. The survey included seven questions rated from one (very 
dissatisfied) to five (very satisfied).  The survey had a minimum score of seven and a maximum 
score of 35 points possible, where 35 indicated the highest possible level of satisfaction.  A 
section for written comments was also provided on the survey.  Content from this narrative 
evaluation data were analyzed and summarized according to common themes.   
Methods of Data Analysis  
 Data was reviewed by the project coordinator for data entry errors.  Frequencies were 
calculated in order to determine the number of individuals who were asked to participate, those 
who agreed to participate, and those who completed the quality improvement project.    
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 The initial step in the data analysis was to determine if the data sets had normal 
distribution, in order to determine the appropriate statistical test(s) to use.  In the project design, 
the initial plan was to use a paired t-test for data elements with normal distribution (Weis, 2012) 
and the Wilcoxon Signed Ranks test for data with a non-normal distribution 
(Statistics.laerd.com, 2020; Weis, 2012).  The test of normality selected was Shapiro-Wilk, 
which is typically used for data sets with less than 2,000 elements (Maths-Statistics-Tutor.com, 
2020; Weis, 2012).  Initial statistical analysis, including mean change and standard deviations for 
A1C and DSMQ scores were calculated in Excel, followed by a more detailed analysis using 
IBM SPSS version 23 (IBM, 2015).  Mean scores for the provider survey were also calculated 
using Excel.   
Outcomes/Results 
 Sample demographics.  A total of 75 patients met the initial inclusion criteria.  After 
excluding those patients empaneled to the non-participating provider, those who were found to 
meet exclusion criteria, and those who were unable to be reached, a total of thirty-one patients 
agreed to participate in the program.  Four of those patients failed to return calls to make an 
initial appointment, leaving a total of 27 patients who participated in this project.   
 Demographic data was not kept on non-participants due to Air Force human protection 
requirements; however, reasons for non-participation were tracked.  Non-participation included 
patients who declined to participate, could not be reached, or those who did not meet criteria 
(Figure 2).  The primary reasons for non-participation were: patient declines (34%), unable to 
reach (23%), and PCM not participating (18%).  Another common reason for non-participation 
was if the patient’s diabetes care was managed by an off base endocrine specialist (11%). 
 
DocuSign Envelope ID: 28A56752-5014-41FF-AF51-8729673AFFC0




Figure 2.  Demographics: Reasons for Non-participation 
  
Descriptive statistics were used to evaluate the sample characteristics which included 
gender, race, and age.   Females made up 56% of the sample, while 44% were male.  White 
patients made up 82% of the sample, with black patients making up 11%, and Asian patients 
making up the remaining 7%.  Data for sex and race are summarized in Figures 3 and 4.  The 
mean participant age was 55 (SD = 9.30), with an age range of 25-72 years.  This sample was 
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Figure 3. Demographics: Sex  
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 For the purposes of statistical testing, only complete data sets were analyzed.  Four 
participants did not complete the post-DSMQ survey and eight participants did not complete a 
post-A1C lab.  Seven of the thirteen participating providers completed the satisfaction surveys.   
 Provider visits.  The goal for this program was to provide 4-5 virtual visits within 3 
months.  Patients participated in an average of 3.07 visits (SD = 1.17) and with a range of 1 – 5 
visits, which indicated participants participated in less follow-up encounters than was the goal.  
This also demonstrated significant variability in relation to number of follow-ups from patient to 
patient.   
 A1C.  The pre- and post- A1C mean difference scores (n = 19) were found to have a non-
normal distribution based on the Shapiro-Wilk’s test (.865, p = .012).   Given the non-normal 
distribution, the Wilcoxon-Signed Ranks Test non-parametric alternative was used for statistical 
analysis.  Data met the assumption of symmetry of difference scores around the mean.   
 The mean of the difference scores in A1C from pre- to post- was -0.75 (SD = 1.75).  A 
Wilcoxon signed rank test revealed a significant difference in scores between the pre- and post- 
A1C (Z = - 2.38, p = .018), suggesting the intervention had a positive impact on A1Cs in this 
sample.  Of the nineteen patients in the data set, sixteen did have a decrease in A1C, of which 
fourteen had a clinically significant A1C reduction (>/= -0.5%).  Three patients had an A1C 
increase.  Data are summarized below in Table 1. 
Table 1 
A1C Statistical Analysis 
Statistic Mean Change (Pre- to Post-)  Statistical Test p-value 
A1C  M = - 0.75, SD = 1.75   Z = - 2.38  p = .018 
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 DSMQ.  The DSMQ total sum score and three of the four subscales (Diet/Nutrition, 
Physical Activity, and Health Care) were found to be normally distributed (p  > .05).  Therefore, 
a paired t-test was used to compare pre- and post- mean difference scores.  The DSMQ total sum 
pre- and post- scores demonstrated a mean improvement of -1.07 (SD = 1.45) and a paired t-test 
demonstrated a statistically significant mean difference (t = -3.40, p = .002).  This suggested that 
the intervention improved the patients’ overall self-rating of diabetes self-care.  The pre- and 
post- healthcare subscales showed a mean improvement (M = -1.30, SD = 1.86) and a paired t-
test demonstrated a significant mean difference (t = -3.33, p = .003).  This suggested that the 
intervention improved patients’ rating of access and utilization of healthcare services/follow-up.  
 The diet pre- and post- subscales demonstrated a small, non-significant mean 
improvement (M = -0.66, SD = 2.03), (t = -1.236, p = .229).  This suggested that the intervention 
did not have a significant impact on patients’ dietary habits.  The physical activity pre- and post- 
subscales demonstrated a small mean improvement  (M = -.77, SD = 2.20) but likewise did not 
demonstrate a significant mean difference (t = -1.686, p = .106).  This suggested the intervention 
did not have a significant impact on patients’ self-rating of their physical activity habits. 
 The DSMQ glucose subscale had a non-normal distribution (p < .05) so the Wilcoxon 
signed rank test was utilized.  The glucose subscale pre- and post- mean difference scores 
showed improvement (M = -1.75, SD = 2.30) which was statistically significant (Z = -3.212; p = 
.001).   This suggested that the intervention led to an improvement in self-ratings of the patient’s 
ability to manage their glycemic levels.  Data are summarized below in Table 2. 
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Table 2 
DSMQ Statistical Analysis 
Statistic                    Mean Change (Pre- to Post-)           Statistical Test         p-value 
DSMQ Sum Score   M = -1.07, SD = 1.45                       t = - 3.40                  p = .002 
DSMQ Glucose       M = -1.75, SD = 2.30                       Z = - 3.21                 p = .001 
DSMQ Diet              M = -0.66, SD = 2.02                       t = - 1.24                  p = .229 
DSMQ Healthcare   M = -1.30, SD = 1.86                       t = - 3.33                  p = .003 
DSMQ Phys Activity  M = - 0.77, SD = 2.20                      t = - 1.69                  p = .106 
  
Provider Survey.  The provider survey mean score was 30.29 (SD = 3.25) out of 35 
possible points, and all seven individual questions demonstrated a mean score of 4.0 or above out 
of 5 possible points, indicating a strong level of provider satisfaction with telehealth.  Open 
ended comments were reviewed for common responses.  One common theme was improved 
A1C values for the patients, exemplified by the comment “my patient had significant A1C 
improvement, positive patient comments!”  Another theme was the positive aspect of having 
more frequent follow-ups, exemplified by the comment “Great program allowing DM patients to 
be more closely monitored and motivated to make TLC and take control of their blood sugars.”  
Several providers commented on the impact of COVID-19 limiting follow-up labs, as 
exemplified by the comment “I think follow ups are great for telemedicine, due to COVID with 
diabetic patients, would have wished to be able to review more labs more often, but patients 
were concerned for exposure.”  One provider discussed the increased time commitment, stating 
“I found the time commitment to go through the motivation interviewing and goal setting to take 
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a lot of time, and may be difficult to maintain.”  One comment that exemplifies the positive 
nature of the responses stated that “every patient's A1C dropped 1-3% in 3 months, this works!!”.   
Synthesis/Limitations/Discussion 
Program data indicated statistically significant mean A1C difference scores pre- and post-
intervention (p = .018).  The mean decrease in A1C of 0.75% is also clinically significant (Little 
et al., 2013).  Given the small number of subjects (n = 19) who completed both pre- and post- 
A1C measurements, several A1C outliers may have impacted the overall results in either a 
positive or negative direction.  There was one significant outlier where a patient had an A1C 
increase from 8.3 to 12.7.  In this particular case, the patient’s pre-A1C was from July 2019 
which was 9 months before the start of the project, although the patient did participate in three 
telemedicine visits.  This patient did not obtain a pre-A1C early in the program as recommended, 
which may have been due to COVID-19 concerns, and it is possible their baseline A1C at 
program start may have actually been much higher.  The patient with the largest decrease in 
A1C, from 9.9 to 6.2, also participated in three telemedicine visits and had a pre-A1C just prior 
to program initiation.   
The overall DSMQ summary score change (n = 23) was statistically significant (p = 
.002), as were the subscales of glucose management (p = .001) and health care utilization (p = 
.003).  The subscales of dietary (p = .229) and physical activity (p = .106) were not found to be 
significant.  This may indicate that more focus is needed in future programs on diet, physical 
activity and/or resource education.  COVID-19 lockdowns occurring in Alaska during this time 
may have limited some patients from engaging in exercise and/or following the recommended 
healthy diet.  It is interesting that subscale ratings increased for health care contact/utilization, 
which may indicate the increased access provided by this program improved patients’ self-rating 
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of healthcare access.  In addition, improved scores for glucose management coincided with the 
mean improvement in A1C scores.   
Seven providers completed the satisfaction survey.  Overall provider satisfaction was 
high, with an average score of 30.29/35.  All seven questions received an average score of 4 or 
higher (satisfied or highly satisfied), indicating providers found the program to be acceptable.  
The provider comments reinforced the positive patient outcomes, particularly in the reductions in 
A1C.  Comments also described frustrations regarding the lack of follow-up A1C’s and 
scheduling issues related to COVID-19.  Some excellent points about future areas for 
improvements including providing additional training on the approach to scheduling 
appointments and more structured education were provided.   
A1C data were limited due to the small sample (n = 19) of individuals with complete 
A1C data sets.  The COVID-19 barrier to patient compliance in obtaining the pre- and post- A1C 
labs was the biggest limitation of this project.  The goal had been to obtain a pre-A1C within 
three months prior to the start of the program, and providers did recommend this to each patient.  
This project began at the same time as local “stay at home” orders began, and military base 
access was restricted.  Due to this limitation, the most recent pre-A1C lab values within the past 
year were accepted for the baseline pre-A1C.  The time differences in pre-A1C had potential to 
impact overall mean A1C change data.  These same issues created limitations in obtaining a 
timely post-A1C, with some patients citing an unwillingness to come in for lab work due to 
COVID-19 safety concerns.  A total of eight patients did not obtain the post-A1C.   
Of the total population of 75 patients who were initially eligible to enroll in the program, 
fifteen patients declined to participate, and one provider did not participate which eliminated 
eight additional patients from participation.  Four patients who initially enrolled in the program 
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never scheduled an appointment and were excluded.  Additional patients were screened out due 
to provider input or not meeting inclusion/exclusion criteria.  In future programs, having a larger 
sample size with more closely controlled pre- and post- A1C lab data would further allow clinics 
to determine the generalizability to glycemic outcomes from this type of program.    
Given that this was a clinical quality improvement project, it was important to look at the 
results from the standpoint of clinical significance.  Given that an A1C reduction of 0.5% is 
known to be clinically significant (Little et al., 2013), a mean decrease in A1C of 0.75% in this 
program did demonstrate a clinically significant reduction in A1C, that was statistically 
significant as well.  Looking at individual A1C scores, fourteen out of nineteen patients had a 
clinically significant reduction in A1C of at least 0.5% which indicates this program was 
successful in improving clinical measures of diabetes care. 
The DSMQ is a reliable and validated survey on diabetes self-care (Schmitt et al., 2016), 
however as with any survey patient’s may over or underestimate where their true levels lie.  For 
example, the Hawthorne Effect (Weis, 2012) may lead patients to over-report improvements.  
Conclusion 
Although this program was designed as a QI project within the Family Health Clinic and 
was not designed to be generalizable outside this clinic, the overall data do indicate that the use 
of telemedicine modalities improved both A1C glycemic and self-care outcomes for patients.  
Given that the Military Health System utilizes the same CPG that was the foundation for this 
project DOD-wide,  it increases the likelihood that these findings may be generalizable to other 
clinics with similar populations.   The change in A1C was statistically significant (p = .018), 
indicating the program improved glycemic outcomes.  The summary self-care score in the 
DSMQ was significant (p = .002 ) indicating the program improved patient reported self-care 
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scores.  The fourteen patients who demonstrated clinically significant outcomes of mean change 
in A1C (decrease of  >/= -0.5%) further demonstrate the potential of the telemedicine program to 
improve clinical outcomes.  Overall, the findings of this project indicated that further well 
designed QI projects and research studies are needed to assess the impact of these modalities.  
Future projects should seek to obtain larger sample sizes.  Establishing programs with tighter 
A1C lab timing and possibly a more structured provider instrument may improve the 
generalizability of this type of diabetes telemedicine program.  Data from this project could also 
be used to target future provider education in diabetes and telemedicine and validate the use of 
telemedicine/virtual medicine in improving diabetes care.   In addition, further work could 
demonstrate if similar outcomes occur when an intervention such as this is conducted by other 
clinical staff such as Clinical Pharmacists or Registered Nurses.  
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Chapter 7: Implications for Nursing Practice 
 Chapter 7 discusses the implications for nursing practice from this project, utilizing the 
DNP Essentials (AACN, 2006) as a framework.  The DNP Essentials are the foundation of the 
DNP degree program and a guide for DNP practice (AACN, 2006).  In this chapter each DNP 
Essential will be related to various aspects of the project.   
DNP Essentials 
DNP Essential I.  Essential I focuses on the scientific underpinnings of practice (AACN, 
2006).  Evidence-based practice supported by research and science is utilized to provide the best 
patient care, which is a fundamental priority for DNP providers (AACN, 2006).  Evidence from 
the literature was utilized to develop the concept of this project and guide each step of its 
implementation.  A critical review and synthesis of the literature was accomplished to determine 
the impacts of various telemedicine modalities on diabetes care, and to identify best practices.  It 
was determined that the evidence supported the telemedicine modality for improving diabetic 
outcomes.  Previous interventions (including meta-analyses, systematic reviews, and RCT’s) 
were analyzed and utilized to guide this project’s implementation.  The data analysis portion of 
the project provided insight into the effectiveness of the interventions.  This DNP project 
interwove the use of science and data with advanced practice nursing to implement a program 
that improves diabetic outcomes.   
DNP Essential II.  Essential II focuses on organizational and systems leadership for 
quality improvement and systems thinking (AACN, 2006).  This project was a clinical quality 
improvement project.  During the project, effective leadership and following a structured process 
within the organization helped lead to successful implementation.  Utilizing Havelock’s Change 
Theory (Havelock, 1973) as an organizational framework helped guide project planning, 
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implementation, dissemination, and evaluation.  This essential stresses the importance of looking 
at healthcare issues with a systems focus (AACN, 2006).  This project was designed to improve a 
system of care (diabetes care within a primary care clinic) and has potential implications not only 
to the population within this clinic but also could be applicable to other military treatment 
facilities and civilian practices who serve similar populations.  The data could be utilized to 
further develop this or other quality improvement projects in the future.  Communication skills 
and working within an organizational hierarchy were required to obtain multiple approvals 
throughout a complex military structure.  The evaluation of potential ethical and financial 
impacts were also important aspects of this project that could affect the system as a whole.   
DNP Essential III.  Essential III involves clinical scholarship and analytical methods for 
evidence-based practice (AACN, 2006).   In this project data was collected on A1C mean 
change, DSMQ score mean changes, and provider survey ratings.  These data were analyzed 
using appropriate statistical methods and software and synthesized to determine the impact the 
project interventions had on patient outcomes.  The understanding and analysis of data is key to 
disseminating knowledge from this project and garnering support for practice change.  AACN 
(2006) states that developing quality improvement projects to promote effective patient care is an 
essential part of DNP education and practice.  This project incorporated the full spectrum of 
scholarship including analyzing evidence in literature, project design, implementation, data 
analysis, dissemination, and practice change.   
DNP Essential IV.   Essential IV focuses on Information Systems/Technology for the 
Improvement and Transformation of Healthcare (AACN, 2006).  This project incorporated 
telemedicine - virtual visits, virtual provider education, and the use of technology to assist in data 
extraction and analysis.  Phone visits were used in this project (as opposed to video visits or 
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telemetry); the review of evidence showed the effectiveness of multiple technology modalities 
for improving diabetes care including telephone visits, video conferencing, telemonitoring, and 
other advanced technologies.   
DNP Essential V.   Essential V describes the use of health care policy for advocacy 
(AACN, 2006).  Data from this project provides further evidence in support of the utilization of 
telemedicine in diabetes care and has the potential to expand the use of telemedicine within the 
military health system.  The Defense Health Agency is driving evidence-based practice within 
the military and data are essential to obtaining buy-in for utilizing telemedicine modalities.  This 
project required the project coordinator to work with multiple leaders and stakeholders at 
multiple levels to advocate for implementation.  During dissemination, the data were provided to 
these same stakeholders with a strong recommendation to continue using these virtual visits for 
improving diabetes outcomes.  
DNP Essential VI.   Essential VI discussed interprofessional collaboration for improving 
patient and population outcomes.  Interprofessional collaboration was absolutely key to the 
multi-disciplinary approach for this project (AACN, 2006).  Many diverse stakeholders were 
involved throughout the medical group.  This project involved physicians, physician assistants, 
nurse practitioners, nurses, technicians, health integrators, patient educators, pharmacists, and 
other allied health professionals.  Collaboration with the patients involved in the study was also 
extremely important.  A key of this essential is the ability to demonstrate leadership and 
communication skills within diverse groups to create change (AACN, 2006).  The framework of 
this project also guided the early and continual involvement of stakeholders throughout the 
project.  Several clinical pharmacists have approached the project coordinator to inquire about 
possibly creating a program for their own diabetes clinic that is based on this program.  This is 
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an example of how interdisciplinary programs can benefit more than one professional area of 
practice.   
DNP Essential VII.   Essential VII describes clinical prevention and population health 
for improving the nation’s health (AACN, 2006).  The overarching goal of this project was to 
decrease the burden of diabetes through secondary and tertiary prevention strategies, identify 
patients at higher risks for complications, and target these patients for intervention through 
telehealth visits.  Certainly, the population with A1C’s greater than 8 have a higher risk for 
complications.  Improving population health and evaluating strategies that impact population 
health (AACN, 2006) were guiding aspects of this project.   
DNP Essential VIII.   Essential VIII describes advanced nursing practice (AACN, 
2006).  Advanced Nursing Practice is demonstrated by the project design and implementation 
being led by an APRN with the support of several other APRNs in the clinic.  Key DNP practice  
essentials used in the project were: developing relationships to improve outcomes, assessing and 
educating patients, and designing interventions based on scientific framework (AACN, 2006).  
Implications 
The diabetes telemedicine project influences and promotes the field of Advanced Practice 
Nursing within the military healthcare system.  This project involved utilizing all elements of the 
DNP Essentials to improve the practice of individual providers, but also to promote a larger 
organizational change enhancing the utilization of telemedicine.  The data demonstrated that 
telemedicine can be used to improve certain aspects of diabetes self-management and showed a 
clinically and statistically significant improvement in A1C scores.  As a DNP student, this 
project utilized and explored all of the DNP Essentials.  Although it is too early to assess the 
long term implications of this program, the data support the continued use of this program within 
DocuSign Envelope ID: 28A56752-5014-41FF-AF51-8729673AFFC0
TELEMEDICINE AND DIABETES  73 
 
the Family Health Clinic and will hopefully be a useful starting point for other PI projects within 
the Military Health System.   Although the project coordinator is no longer a provider in this 
clinic, communication continues on ways to continue using the key elements of this project in 
practice.   
Limitations 
The biggest limitations of this project were the small sample size and missing elements of 
data.  The short term nature of this project did not explore the effects a longer program may have 
had on outcomes or whether clinical outcome improvements would be sustained over time.  As 
discussed in the statistical analysis section, COVID-19 also significantly impacted this project.  
In addition to creating challenges for patients obtaining labs, COVID may have impacted other 
aspects of diabetes self-care.  During lock-downs, gyms were closed throughout the local area 
and people were encouraged to stay home, which may have limited exercise capabilities for 
many patients.  Dine in restaurants were also closed, limiting food service to take out and fast 
food establishments, which may have limited healthy food options.  Income changes for some 
may have also led to changes in the ability to access healthier foods.   Despite these limitations, 
this program demonstrates potential for improving clinical outcomes in diabetic patients. 
Conclusion 
The DNP Essentials provided structure and guided the development, implementation, and 
dissemination of this evidence based project.  An understanding of the DNP Essentials (AACN, 
2006) is key to DNP practice and strengthens individual health, population health, and NP 
practice.    
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Chapter 8: Summary and Conclusion 
This DNP project focused on the development and utilization of a provider directed 
telemedicine follow-up program with the purpose of improving glycemic outcomes and self-care 
for uncontrolled Type 2 Diabetics.  Diabetes is a global public health concern (Lee, Chan, Chua, 
& Chaiyakunapruk, 2017) and it is well documented that many diabetic patients never reach their 
treatment goals (Schmittdiel et al., 2008).  Limited access to care, time constraints, and 
geographic distance often reduce the opportunity for providers to address all the aspects of 
diabetes management during face to face clinic encounters.  The project coordinator developed 
the idea for this project after observing a lack of consistent use of telemedicine practices 
recommended in the VA/DOD CPG (2017) specific to diabetes follow-up in the Family Health 
Clinic.  This chapter summarizes the key points and outcomes of the project. 
Key Points  
Project goals.  The purpose of this project was to assess the acceptability and utilization 
of an intensive provider-implemented telemedicine follow-up program aimed at improving 
glycemic outcomes and self-care in adult patients with poorly controlled Type 2 Diabetes. The 
program was developed to provide a standardized approach to the follow-up care delivered by 
providers utilizing evidence-based telemedicine practices and included usual standards of care.  
Methods.   Havelock’s Theory of Change (1973) was utilized as a framework for the 
development and implementation of this quality improvement project.  The project utilized a pre-
test post-test design with laboratory and survey data to measure change in A1C, diabetes self-
care management scores (DSMQ questionnaire), and a post-test only provider satisfaction 
survey.   
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Adults with Type 2 Diabetes and a documented A1C greater than 8.0 meeting inclusion 
criteria were offered telephonic follow-up with their primary care provider every two to three 
weeks for three months.  Providers utilized an instrument developed for this project which was 
based on the previous work of Gervera & Graves (2015).  Telephone visits focused on 
medication management, diabetes self-management education such as self-monitoring blood 
sugar, healthy diet and exercise changes, and referral to various resources. 
Implementation and resources.  Once all necessary approvals were obtained, providers 
and staff were trained on the project goals, instrument, and the VA/DOD Clinical Practice 
Guidelines (2017).  Project implementation began in April 2020 and continued for three months.  
Patients meeting inclusion criteria were contacted and pre -A1C and -DSMQ data were obtained.  
The timing of the program happened to coincide with the outbreak of COVID-19 worldwide.  
COVID-19 created a number of barriers to overcome, including the requirement for virtual 
provider/staff training and follow-up, and lack of complete lab data from some patients.   
This project was cost neutral, and the time commitment from providers was consistent 
with estimates developed during the planning phase of the project.  No unexpected costs were 
incurred.  At the end of the three month program, a post-A1C and post-DSMQ were obtained as 
well as a post-survey from participating providers.  Data were analyzed and the outcomes were 
disseminated. 
Significance of results.   The data demonstrated both statistically (p = .018) and 
clinically significant (mean A1C decrease of 0.75) improvement in A1C.  In addition, 
statistically significant improvements in the DSMQ sum score and subscales of glucose 
management and healthcare utilization were demonstrated.  This indicated that the program had 
positive outcomes for glycemic control and self-care for the participants.  The provider surveys 
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demonstrated overall provider satisfaction with this program.  These findings demonstrate 
positive outcomes from utilizing telemedicine for more frequent follow-up with poorly 
controlled diabetics and are very promising for the future use of telemedicine to improve 
diabetes outcomes.  Based on review of the data, the project goals were accomplished. 
Self-reflection and summary of learning.  The management of diabetes continues to be 
a challenge for clinicians.  This project incorporated all eight DNP essentials (AACN, 2006) and 
utilized an evidence-based approach to develop an intense telemedicine follow-up program.  This 
program demonstrated a positive impact on clinical outcomes of adults with uncontrolled Type 2 
Diabetes.  Educating providers and providing an instrument to guide the program helped ensure 
consistency.   In the future, larger sample sizes and more consistency in the timing of labs may 
provide additional evidence to evaluate the impact of telemedicine in the management of 
diabetes. 
Conclusion    
This project demonstrated positive outcomes in both glycemic control, patient self-care, 
and provider satisfaction.   Findings from this evidence based project support that the project 
goals were accomplished.   This project demonstrated that Havelock’s Theory (1973) provided a 
very successful framework for the planning, implementation, evaluation and dissemination of the 
project.  Although Havelock’s Theory is not specifically a nursing theory, it enabled successful 
navigation of the project within a complex military system involving multiple stakeholders and 
hierarchy, and through the sometimes chaotic operational tempo due to COVID-19.  The success 
of the framework is demonstrated by the positive clinical outcomes and the successful 
completion of this project.     
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Appendix A: Evidence Table  
Table A-1 
Evidence Table 





Data Analysis Study Findings/Significance Appraisal of worth to 
practice/ strength of the 














941 Adults with 
T1DM/T2DM w/ 
A1C > 7.0 in South 
Bronx, NY. 67% 
Latino, 28% AA. 
Intervention group 
rec'd 4 phone calls in 
12 months if A1C > 
7.0, and 8 phone calls 
in 12 months if A1C 
> 9.0.  Trained health 
educators (supervised 
by physicians and 
diabetes educators) 
provided DSME.  













regression model;  






Mean A1C decreased by 0.9% 
(SD = 0.1) in telephonic group, 
compared to 0.5 (SD = 0.1) in 
print only group.  Telemedicine 
intervention (phone calls) 
associated with 0.4% A1C 
decrease when compared to 
standard print only intervention 
(p = 0.01).  Those with A1C > 
9.0 had more significant 
reductions.  Percent of 
participants in telemedicine 
arm with A1C decrease of 1% 
was 37.4%; and 1.5% A1C 
decrease was 26.7% (p = 0.01).  
Both groups similar 
improvements in self-care 
activities (SDSCA) and med 
adherence (Morisky MA).   
Limitations: may not be 
generalizable given 
somewhat homogeneous 
population primarily Latino 
in localized area of NYC; 
patient attrition.  Strengths: 
large population over 1 
year, RCT.  Demonstrated 
statistical and clinical 
significance.  Level 2 
















50 Veterans; T2DM; 
A1C > 9.0 for at least 
1 year; 
predominantly male; 
average age 60's; 
veterans from VA 
system in NC, 
predominantly 




calls every 2 weeks 





utilized.  Physician 













analysis - mean 
reduction in A1C 




Telemedicine program led to 
A1C improvement - 1.0% at 3 
months (95% CI -1.7 to -0.2%, 
p = .012). A1C improved 
average -1.0% at 6 months 
(95% CI -2.0 to -0.0, p = .050); 
Self Care Inventory-Revised 
estimated difference of 7, p = 
.047 - statistically significant. 
Limitations: Unblinded 
randomization; single center 
pilot RCT, small and 
homogenous population. 
Designed more for 
feasibility than outcomes.  
Strengths: Limited attrition, 
RCT.   Population translates 
well to the military retiree 
population.  Statistical and 
clinical significance.  Level 
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Table A-1 (Continued) 


















T2DM; > 18 
years old; 255 
participants; 






skills, or control.  
South Carolina.  
Delivered by a 
trained Health 
Educator. 
DV = A1C 
(measured at 
3,6,12 months) 
Chi square tests, 
ANOVA, 
ANCOVA for A1C 
change. 
Significant reduction in A1C 
over time (- .07, P < .001) 
across all groups, but no 
significant differences were 
found between intervention and 
control groups (knowledge: 
0.49, p = 0.123; skills: 0.23, p 
= 0.456; combined: 0.48, p = 
0.105). Absolute change from 
baseline at 12 months for all 
treatment arms was 0.6%. 
Limitations:  focused only 
on African-American 
population, telemed 
interventions delivered by 
non-medical health coach 
(not nurse or provider).  
Strengths: RCT, Blinded 
treatment assignments, 
adequate statistical analysis, 
shows telemed interventions 
comparable to usual care.  
All treatment arms showed 
clinically significant A1C 
reduction over 12 months.  











care on A1C 
(glycemic 
control) 
111 RCT's; adult 








37% nurses and 
29% physicians.  
DV = A1C Mean difference in 
A1C; using random 
effects modeling.  
Univariate meta-
regression. 
Telemedicine lowered A1C by 
0.57% within 3 months (CI not 
listed); telemed interventions 
that allowed medication 
adjustments (provider or nurse 
driven) had greater reduction in 
A1C  (-0.23%, 95% CI -0.42% 
to - 0.05%, no p value reported 
but described as significant) 
Limitations: assessed both 
type 1 and type 2 diabetes. 
Some statistics (CI, p values 
not fully provided in the 
article, however all 
individual study data are 
provided).  Strengths: risk 
of bias assessed using 
Cochrane collaboration tool, 
when 3 specific studies 
were removed publication 
bias was not significant; 
large sample size, able to 





clinical significance. Level 



















versus control as 










Significant decrease in A1C 
compared to standard care 
(0.69% vs 0.18%, p = .022).  
At six months, the difference 
was no longer significant.  Two 
way ANOVA significant 
effects found (p = .003) 
Limitations: selection bias, 
no medication titration.  
Strengths: studied 
telemedicine as ADD ON.  
Clinical and statistically 
significant.  Level 2 
evidence, RCT.  Clinically 
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Table A-1 (Continued) 





























DV = A1C Mean A1C +/- SD; 
ANCOVA 
All 3 groups showed a 
significant reductions in A1C, 
however adjusted A1C similar 
across all groups - no statistical 
significance between groups (-
0.66% – 1.03% in the control 
group, -0.66% – 1.09% in the 
telemonitoring group, and -
0.81% – 1.05% in the 
telemedicine group, p < 0.001 
each). 
Limitations: selection bias, 
short follow-up.  Strengths: 
compared provider directed 
telemedicine to 
telemonitoring and usual 
care.  Level 2 evidence, 
RCT.  Clinically and 
statistically significant 
reductions across all groups, 
though no significant 





















A1C > 7.5.  
Weekly care calls 
from diabetes 
coaches - self 
management 
education.  F/U 
A1C at 26/52 
weeks. 
DV = A1C 
(primary outcome 
at 12 months); 
also reassessed at 
26 and 52 weeks. 




A1C reduced by 1.1% (p < 
.0001). Estimated treatment 
difference in the adjusted 
model was 0.8% (95% CI 1.1 - 
0.5, p < 0.0001). At 26 and 52 
weeks treatment superiority at 
0.6% (95% CI 1.0 - 0.3, p < 
0.0001; 95% CI 0.9-0.2, p < 
0.001).  
Limitations: attrition, 
greater in control group.  
Multiple interventions in a 
program makes it difficult 
to attribute reduction to one 
specific factor.  Strengths: 
RCT with adequate 
statistical analysis.  Level 2 
Evidence.  Shows 
effectiveness in advanced 
DM.  Clinically significant 
reduction reported.  Showed 
effectiveness persisted over 
time to 52 weeks.  
STRONG EVIDENCE. 



















settings; pubs = 
107; 20,501, 




A1C; 50% studies 
in North America; 
both males and 
females; median 
follow up  = 6 
months or less;  








change in A1C 
from baseline to 








evaluated using I2 
statistics; 
multivariable model 
with adjusted R2; 
mean difference 
A1C with 95% CI's.  
Telemedicine was superior to 
usual care improving A1C , 
mean difference -0.43% (95% 
CI, -0.64% to -0.21%),  p < 
.001; substantial heterogeneity 
(Q=88,052, I2=99.9%, 
H2=966, p < .001).  Larger 
effects in shorter duration 
studies.  Meta-regression 
analysis showed no statistically 
significant inconsistencies for 
all outcomes.  No telemedicine 
strategies were significantly 
better than the others. 
Limitations: Heterogeneous 
studies - variations in types 
of telemedicine, type of 
intervention provider, 
lengths of studies, 
population/locations.  Usual 
care is not consistently 
defined.  Variability of bias 
assessment in studies.  Lack 
of long term follow-up. 
Strengths: reviewed large 
population from multiple 
RCT's.  Largest review of 
kind to date.  Meta-
regression analysis 
conducted (93 trials), no 
statistically significant 
inconsistency for outcomes.  
Level 1 Evidence.  
Somewhat clinically  
reduction A1C 0.37% - 
0.71%.  MODERATE TO 
STRONG EVIDENCE. 
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Table A-1 (Continued) 
Evidence Table  





versus face to 
face 
endocrinology 





male; mean age 
62.8; Denver VA 
System. 
DV = A1C  Student's t-test, 
Fisher's exact test, 
linear regression 
model, mean A1C 
change w/ 95% CI. 
Decrease in A1C from baseline 
to visit 1 in telemed group was  
0.277 percentage points greater 
than decrease in A1C from 
baseline to visit 1 in the clinic 
visit group (95% CI: 0.741 
percentage points greater drop 
to 0.186 percentage points 
lesser drop).  p = .2347 (not 
statistically significant).  
Showed estimated $94.79 per 
visit saved per patient in travel 
costs.  
Limitations:  retrospective, 
non-randomized design.  
Short term.  Strengths: 
provider driven 
telemedicine consultations, 
indicates telemedicine care 
is equivalent to standard 
care with specialty consults 
for management.  Veteran 
population, reasonable 
sample size.  Level 4 
evidence.  MODERATE 
EVIDENCE. 
Odnoletk
ova et al. 
(2016) 
Study effect 











adults age 18-75 
years; five RN 
led coaching 
sessions 
DV = A1C  Linear model for 
repeated measures 
with unstructured 
covariance matrix - 
continuous 
outcomes.  Mann 
Whitney U and 
Fisher Exact Tests 
At 6 months, between-group 
difference in effect on A1C 
between intervention and 
control was -2 (95% CI -4 to -
1) mmol/mol [-0.2 (95% CI -
0.3 to -0.1)%; p =0.003. 
Limitations: Authors 
discuss concern for positive 
self-selection (patients self-
recruited, indicating more 
motivated patients/selection 
bias).  Strengths: large 
sample, heterogenous, 
utilized reproducible 



















DV = A1C  95% CI's, statistical 
heterogeneity 
between studies 
assessed using I2 
Tele support 4 RCT's: 2 
reported lower mean A1C (7.8 
+/- 0.8 vs 8.9 +/- 1.0, p < .01) 
and (7.6 +/- 1.1 vs 8.1 +/- 1.5, 
p = .06) and 2 reported higher 
A1C (8.8 +/- 0.9 vs 7.6 +/- 1.0, 
p = .252) and (6.9 +/- 1.5 vs 6.6 
+/- 1.1, p not reported)  
Limitations: older SR (10 
years), only tele support 
data is relevant to this 
project, heterogenous 
studies; assessed multiple 
variables not just A1C. 
Mixed results.  Strengths: 
adequate statistical analysis, 
larger sample.  Level 1 
Evidence.  MODERATE 
EVIDENCE. 
Rasmusse




n of home 
telemedicine 




DV = A1C Mean change A1C, 
t-test, Mann-
Whitney U test or 
ANOVA. 
A1C was statistically lower in 
telemedicine group (-15% vs - 
11%).  Limited discussion of 
statistical analysis results. 
Limitations: short 
observation period, small 
sample size, limited 
discussion of statistical 
analysis.  Strengths: no 
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Table A-1 (Continued) 
















via the usual 
diabetes clinic 
consultation. 
199 T1DM and 
T2DM patients in 
telemed arm; 83 
in usual care; 
outpatient 
specialist clinic. 
DV = A1C, 
patient 
satisfaction. 
Mean +/- standard 
deviation A1C; t-
tests, chi square 
tests.   
Both groups small decrease in 
A1C; Statistically insignificant 
differences in A1C between 
groups (telemedicine -1.01% vs 
usual group - 0.68%, p = .19).  
Surveys showed 99.3%. 
Patients felt easier to get care. 
Limitations: A1C of both 
groups was not matched, 
smaller control group.  
Strengths: compared 
telemedicine vs usual care, 
provider driven 
consultations.  No 
significant difference 
between the two groups.  
Level 2 Evidence.  



















137 T2DM; 64 
NP group and 73 
diabetic educator 
group 




A1C significantly lower in NP 
management arm at 3 and 6 
months (0.7 % p < .001), both 
groups A1C improved 
significantly from baseline.   
Limitations: No blinding, 
participant attrition, missing 
A1C values.  Does not 
differentiate if increased 
provider contact, med 
management, or 
telemonitoring contributed 
to improved results in NP 
group.  Only 1 NP did 
intervention.  Strengths: 
RCT, use of NP performing 
intervention which includes 
med management, DSME 
education, monitoring 
SMBG.  Level 2 
EVIDENCE.  STRONG 
EVIDENCE.   
















on A1C; 9,258 pts 
with diabetes 
(T1DM & 
T2DM); length of 
study 6 months or 
less = 30, more 
than 6 months = 
25; telecon = 18 
RCT's, telemon = 
37 RCT's; 17 in 
US, 14 in Europe, 
13 in Asia, 1 in 
Australia; age 
range 11.9-71. 
DV = A1C Effect sizes, 
standardized mean 
difference using 




control arms.  
Stratified results 
within subgroups - 
type of DM, age, 
duration, and type 
of telemed 
intervention.  Q 
statistics used to 
assess 
heterogeneity.   
Telemedicine showed more 
signif. A1C reduction (Hedges 
g =  -0.48, p = < .001).  
Telemed most effective treating 
T2DM (g = -0.63,  p = < .001).  
Telemedicine more effective in 
age > 40 (Hedges g = -0.53, p < 
.001); programs 6 months or 
less more reduction (g = - 0.56, 
p < .001).  Teleconsultation is 
more effective than 
telemonitoring (g = -0.62, p < 
.001) vs (g = -0.40, p < .001).  
No statistical significance in 
results between low and high 
impact journals. 
Limitations: Heterogeneity 
within 55 RCT's - 
particularly populations 
(T1DM and T2DM).  Risk 
of publication bias in 
RCT's.  Subgroup analysis 
did not account for 
differences in baseline A1C 
across groups.  Strengths: 
multiple RCT's  Evidence 
supports effectiveness 
particularly in 
T2DM/telecon/age > 40  
translates to population 
focus.  Level 1 Evidence.  
Clinically significant 
reduction in A1C.  
STRONG EVIDENCE. 
 
DocuSign Envelope ID: 28A56752-5014-41FF-AF51-8729673AFFC0
TELEMEDICINE AND DIABETES  87 
 
Table A-1 (Continued) 
Evidence Table  
Suksomb


















DV = A1C Mean difference in 
change of values 
for A1C with 95% 
CI's; fixed effect 
and random effect 
models were used.  
I2 was used to 
assess variability.   
Telephone intervention did not 
significantly improve glycemic 
control pooled mean difference 
- 0.38%, 95% CI -0.91% to 
0.16%).  I2 = 85% indicating 
significant heterogeneity of 
studies.   
Limitations:  only 5 small 
RCT's - Significant 
heterogeneity of studies; 3 
studies reported as low risk 
of bias, 2 studies high risk 
of bias; poor discussion of 
statistics and population.  
Strengths: specifically 
focused on telephone based 
interventions.  Limited 
clinical significance.  Level 
One Evidence.  WEAK 
















Hispanic; age 55 
or >, New York. 
4-6 week follow 
up visits with 
RN/Dietician for 
5 years via video 
conference 
DV = Summary 
of Diabetes Self 
Care Scale 
(SDSCA) - 
baseline and 5 
year follow-up.  
A1C correlated to 
self-care scale. 
Non-linear models 
for covariance were 
used. 
Number days performing self-
care increased in the treatment 
group (p < .001).  Limited 
discussion of statistics. 
Limitations: SDSCA is self-
report scale.  Population 
homogenous.  Limited 
discussion of statistical 
analysis.  Measured A1C 
but did not focus on 
glycemic change.  
Strengths: large sample, 
long term follow up.  Level 
2 Evidence.  WEAK 
EVIDENCE. 
Wu et al. 
(2010) 
To examine 













1764 patients.  
1334 with T2DM.  
Mean age 63 
years old, 50/50 
male and female.  
Therapy 
adjustment part of 




visit 20 mins. 




Mean difference A1C 
equivocal change - 0.44 (95% 
CI -0.93 to 0.06 p = 0.08) in 
favor of telephone intervention.  
Statistically significant finding 
that the more intensive 
interventions by healthcare 
provider showed standard mean 
difference -0.84 (95% CI - 1.67 
to 0.0, p = 0.05). 
Limitations: significant 
heterogeneity in studies.  
Strengths: clinically 
significant showing more 
intense provider involved 
interventions have better 
outcomes.  SR/MA large 
diverse populations.  Level 
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Table A-1 (Continued) 





















DV=A1C Difference in mean 
A1C with 95% CI;  
heterogeneity 
assessed using  x2,  
Cochran Q statistic, 
and quantified by 
I2.  Random or 
fixed effects models 
were used based on 
heterogeneity.   
Decrease in A1C across all 
studies of - 0.37% (95% CI -
.49 to - .25, p < .001).  
Telephone based subgroup 
decreased A1C -0.53 (95% CI - 
0.81 to -0.26, p < .001).   
Limitations: Significant 
heterogeneity in studies 
lengths and telemedicine 
modalities used; none of 
RCT's able to blind 
participants - concern for 
Hawthorne effect; 
evaluation of the studies 
indicated risks of 
publication bias; only 12/35 
studies were telephone 
based, rest were internet 
based (though some of the 
internet studies did involve 
phone follow up on results)  
Strengths: Validity of each 
study assessed using risk of 
bias assessment tool. 
Detailed discussion 
reliability of meta-analysis; 
detailed discussion of 
statistics and process used 
to limit bias.  Telephone 
subgroups had clinically 
significant A1C drop.  
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Appendix B: Synthesis Table 
Table B-1 
Synthesis Table 
Studies Design Sample Level of 
Evidence 




Intervention(s) Outcome (Glycemic 
Control = A1C) 
Chamany et 
al. (2015) 








4x/12 mo or 
8x/12 mo 
Telephone DSME - med 
compliance, goal 
setting, problem solving, 
diet, exercise. 







N = 50; 
T2DM 






Every 2 weeks 




Telephonic; RN DSME 
w/ physician guided 
medication management 
↓ 





N = 255; 
T2DM 







Telephone Telephonic; Health 




groups; all 4 arms 
showed clinically 
significant A1C ↓ 
Faruque et 
al. (2017) 





Level 1 / 
Moderate 
Variable Variable Variable Various telemedicine 
interventions including 
telephonic; nurses, 





RCT N = 165; 
T2DM 
Level 2 / 
Strong 




Video telemedicine: RN ↓ 
Jeong et al. 
(2018) 
RCT N = 338; 
T2DM 

















groups; all 3 groups 









N = 202; 
T2DM 




Weekly for 12 
weeks; repeat 





Telephonic visits w/ 
diabetes coaches with 
DSME, telemonitoring. 
↓ 
Lee et al. 
(2017) 
SR/MA N = 107 
RCT; 
T2DM 
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Table B-1 (Continued) 
Synthesis Table 
Odnoletkov





N = 684; 
T2DM 




6 and 18 month 
measures 
Telephone Telemedicine coaching 








Level 1 / 
Moderate 
Variable Variable Variable Multiple telemed 
modalities; 
heterogenous 
2 ↓ and 2 ↑ 
Rasmussen 
et al. (2015) 
RCT N = 40; 
T2DM 










Video telemedicine; RN 
w/ physician support 
↓ 





















usual clinic care 
Stone et al. 
(2010) 
RCT N = 137; 
T2DM 








Monthly calls, 3 







monthly with NP versus 
monthly RN educator 
telephone visits 
Significant ↓ A1C in 
NP group vs RN 
group; both groups ↓ 
A1C 
Su et al. 
(2016) 





Level 1 / 
Strong 





m et al. 
(2014) 
SR/MA N = 5 
RCT 
Level 1 / 
Weak 
Variable Variable  Variable.  Telephonic only No statistically 
significant 
difference 
Trief et al. 
(2013) 
RCT N = 1665; 
T2DM 







Every 4-6 weeks 













to usual care 
Wu et al. 
(2010) 





Level 1 / 
Moderate 






significant A1C ↓ 
Zhai et al. 
(2014) 
SR/MA N = 35 
RCT 
Level 1 / 
Strong 
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Appendix C: Organizational Hierarchy (Step One of Havelock’s Theory) 
 
US Air Force HRPO 
673 Medical Group Commander 
673 Medical Group Deputy Commander 
673 Medical Group Chief Nurse 673 Medical Group Chief of Medical Staff 
673 Medical Operations Squadron Commander 
673 Medical Operations Squadron Superintendent 
673 Family Health Clinic Flight Commander 673 Family Health Clinic Medical Director 
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Appendix D: Permission to Modify Instrument 
 
From: Jonathan Beatty <jrbeatty@alaska.edu> 
Sent: Sunday, November 17, 2019 8:54 PM 
To: Gervera, Kelly J. <Kelly.Gervera@va.gov>; agraves@ua.edu 
Subject: [EXTERNAL] Integrating Diabetes Guidelines into Telehealth Screening Tool (2015) 
Dr. Gervera, 
I am a DNP student at the University of Alaska, and a full time FNP in the US Air Force.  I am 
working on my DNP project which involves creating a provider directed intense telemedicine 
follow up program for poorly controlled type 2 diabetes in our Air Force Family Medicine 
Clinic.  The tool you developed in your 2015 article for the EHR correlates well with some of the 
goals of this project.  I was wondering if you would be willing to allow me to modify your 
instrument for use in my project.  We utilize the VA/DOD clinical guidelines as well.  I would 
make a number of additions/deletions to reflect current guidelines and it would be more provider 
specific.  I certainly would credit your work, I just wanted to make sure it wasn't copyrighted or 
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Gervera, Kelly J. <Kelly.Gervera@va.gov> 
 
Wed, Nov 20, 






I think it would be great. Go for it.  I developed my instrument to guide nurses in their f/u calls 
and to get them to dig deeper in their management of patients. Of course, there is a fine line to 
making it simple and convenient (so as not to be rejected by staff) and still cover 
guidelines.  And you are correct, the VA is ahead of DoD and as far as telehealth, and they are 
not slowing down.  Not sure of your time zone but you can call me most times.  My cell phone 
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Appendix E: Telemedicine Diabetes Program Instrument 
Telemedicine Diabetes Program Instrument  
Patient Name:    Date of Birth: 
Encounter Date:   Visit #:  1 2 3 4 5 6 
A1C Goal: 
 
Record Review (if overdue please order as clinically indicated): 
Date/result of last A1C (every 3 months): 
Date last lipid panel (annually):  
Date of last microalbumin (annually): 
Date of last CMP/BMP (annually): 
Date of last eye exam (annually): 
Date of last foot exam (annually):  
Date of last IN PERSON provider physical exam (physical exam due every 6 months): 
Date of last flu vaccination (annually): 




____ Discuss most recent A1C result and set patient specific A1C goal 
 
____ Discuss/order recommended screenings listed above if due/overdue 
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____ Discuss home blood glucose monitoring (SBGM) results and goals 
 
____ Discuss concerns related to weight management and set weight loss goals 
 
____ Discuss concerns related to exercise and set personalized goals 
 
____ Discuss concerns related to diet, and provide healthy diabetic diet recommendations (ADA, 
Mediterranean, etc.) 
 
____ Refer to Nutrition or Diabetes Class if indicated 
 
____ Review medications, assess concerns related to medications or side effects, and discuss 
importance of medication adherence 
 
____ Assess for any hypoglycemic events and discuss management, if indicated 
 
____ Adjust medications or dosing if clinically indicated 
 
____ Refer to Clinical Pharmacist for aggressive management if clinically indicated 
 
____ Discuss concerns related to anxiety, depression, stress management, or psychosocial issues 
and offer BHOP appointment if indicated 
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Appendix F: Provider Telemedicine Satisfaction Survey 
Provider Telemedicine Satisfaction Survey 
Please answer the following questions using the following Likert scale: 
1. Very dissatisfied 
2. Dissatisfied 
3. Neither satisfied nor dissatisfied 
4. Satisfied 
5. Very satisfied 
 
How would you rate the overall acceptability of this telemedicine program? 
1  2  3  4  5 
 
How would you rate the acceptability in terms of the interaction with your patients? 
1  2  3  4  5 
 
How would you rate the acceptability in terms of the time spent with your patients? 
1  2  3  4  5 
 
How would you rate this intervention’s impact on your patient’s diabetic self-management?  
1  2  3  4  5 
 
How would you rate this intervention’s impact on your patient’s glycemic control? 
1  2  3  4  5 
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How would you rate your satisfaction with the tool utilized in this program? 
1  2  3  4  5 
 
Did having the DSMQ questionnaire impact your clinical decision making? 
1  2  3  4  5 
 
 
TOTAL SCORE:    / 35 
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Appendix G: Diabetes Self-Management Questionnaire (DSMQ) 
 
The following statements describe self-care activities 
related to your diabetes. Thinking about your self-care 
over the last 8 weeks, please specify the extent to which 
each statement applies to you. 
Note: If you monitor your glucose using continuous 
interstitial glucose monitoring (CGM), please refer to this 






to me to 
a 
conside
r-able   
degree 
applies 






apply   
to me 
1. I check my blood sugar levels with care and attention. 
☐ Blood sugar measurement is not required as a part of 
my treatment. 
☐3 ☐2 ☐1 ☐0 
2. The food I choose to eat makes it easy to achieve optimal 
blood sugar levels. 
☐3 ☐2 ☐1 ☐0 
3. I keep all doctors’ appointments recommended for my 
diabetes treatment. 
☐3 ☐2 ☐1 ☐0 
4. I take my diabetes medication (e. g. insulin, tablets) as 
prescribed. 
☐ Diabetes medication/insulin is not required as a part of 
my treatment. 
☐3 ☐2 ☐1 ☐0 
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5. Occasionally I eat lots of sweets or other foods rich in 
carbohydrates. 
☐3 ☐2 ☐1 ☐0 
6. I record my blood sugar levels regularly (or analyse the 
value chart with my blood glucose meter). 
☐ Blood sugar measurement is not required as a part of 
my treatment. 
☐3 ☐2 ☐1 ☐0 
7. I tend to avoid diabetes-related doctors’ appointments. ☐3 ☐2 ☐1 ☐0 
8. I do regular physical activity to achieve optimal blood 
sugar levels. 
☐3 ☐2 ☐1 ☐0 
9. I strictly follow the dietary recommendations given by my 
doctor or diabetes specialist. 
☐3 ☐2 ☐1 ☐0 
10. I do not check my blood sugar levels frequently enough as 
would be required for achieving good blood glucose 
control. 
☐ Blood sugar measurement is not required as a part of 
my treatment. 
☐3 ☐2 ☐1 ☐0 
11. I avoid physical activity, although it would improve my 
diabetes. 
☐3 ☐2 ☐1 ☐0 
12. I tend to forget to take or skip my diabetes medication (e. 
g. insulin, tablets). 
☐3 ☐2 ☐1 ☐0 
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☐ Diabetes medication/insulin is not required as a part of 
my treatment. 
13. Sometimes I have real ‘food binges’ (not triggered by 
hypoglycaemia). 
☐3 ☐2 ☐1 ☐0 
14. Regarding my diabetes care, I should see my medical 
practitioner(s) more often. 
☐3 ☐2 ☐1 ☐0 
15. I tend to skip planned physical activity. ☐3 ☐2 ☐1 ☐0 
16. My diabetes self-care is poor. ☐3 ☐2 ☐1 ☐0 
DSMQ©Dr Andreas Schmitt, 2013 
DSMQ – United Kingdom/English - Original version 
DSMQ_AU1.0_eng-GBori 
 
Sample Copy, Do Not Use Without Permission 
 









Appendix H: IRB and HRPO Approval 
Research & Graduate Studies  
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UNIVERSITY of ALASKA ANCHORAGE  
3211 Providence Drive Anchorage, Alaska 99508-4614 T 907.786.1099, F 907.786.1791 www.uaa.alaska.edu/research/ric  
 
DATE: March 26, 2020  
TO: Jonathan Beatty, MSN 
FROM: University of Alaska Anchorage IRB 
PROJECT TITLE: [1571403-2] A Telemedicine Follow Up Program to Improve Glycemic 
Outcomes in Adult Patients with Uncontrolled Type 2 Diabetes  
SUBMISSION TYPE: New Project  
REVIEW TYPE: Expedited Review 
ACTION: DETERMINATION OF NOT HUMAN SUBJECTS RESEARCH 
DECISION DATE: March 26, 2020  
Thank you for your submission of your HSR Determination Request. The University of Alaska 
Anchorage IRB has determined this project does not meet the definition of human subject 
research under the purview of the IRB according to federal regulations.  
We wish you success in executing your program evaluation of this important intervention for our 
veterans facing health challenges.  
We will retain a copy of this correspondence within our records.  
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If you have any questions, please contact Robert Boeckmann at (907) 786-1793 or 
rjboeckmann@alaska.edu. Please include your project title and reference number in all 
correspondence with this office.  
 
Robert J. Boeckmann, Ph.D Chair, Institutional Review Board Department of Psychology 
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USAF Pentagon AF-SG Mailbox AFMSA-SGE-C <usaf.pentagon.af-sg.mbx.afmsa-sge-c@mail.mil> 
 
   
 
 
to Jonathan, me, Sarah, Brett, Peter, Jill, USAF 
 
 
SUBJECT: Air Force Medical Readiness Agency (AFMRA/SGE-C) Human Research Protection 
Official (HRPO) Review of FSG20200006, “A Telemedicine Follow Up Program to Improve 
Glycemic Outcomes in Adult Patients with Uncontrolled Type 2 Diabetes” submitted by 
Jonathan Beatty, MSN, University of Alaska Anchorage 
  
References:  (a) 32 CFR 219, 19 January 2017, Protection of Human Subjects 
                       (b) DoDI3216.02_AFI40-402, 10 September 2014, Protection of Human Subjects
 and Adherence to Ethical Standards in Air Force Supported Research 
  
1. In accordance with Reference (a) and Enclosure 3, Section 4c(1) of Reference (b), the 
AFMRA/SGE-C HRPO has reviewed and concurs with the IRB’s determination that the activity 
does not qualify as research under Section 219.102(l) of Reference (a). 
2. The activity is a clinical quality improvement project that will assess the acceptability and 
effectiveness of implementing the VA/DoD clinical practice guidelines for Type 2 Diabetes in 
the 673d Medical Group, specifically implementing an intense provider-conducted telephonic 
follow up program to improve glycemic outcomes and self-management of patients with 
uncontrolled Type 2 Diabetes.  There is no intent to develop or contribute to generalizable 
knowledge.  The results of this activity will not be generalizable to uncontrolled Type 2 diabetic 
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patients outside of the 673 MDG. The results will only be applicable to uncontrolled Type 2 
diabetic patients within the 673 MDG and this activity was customized for the specific patients at 
673 MDG. For example, while the providers will be using the same instrument to guide their 
telephonic visits, each provider will use the instrument solely as a guide and will customize the 
use of the tool for each individual patient's clinical needs. The list of eligible patients, while 
meeting the eligibility criteria defined within the write up, will be further narrowed at the 
discretion of the participating providers who will exclude patients whom they conclude are poor 
candidates for this approach, which is actually how the tool will be used at 673 MDG if the 
results of the quality improvement project are favorable.  
3. Contact AFMRA/SGE-C at usaf.pentagon.af-sg.mbrx.afmsa-sge-c@mail.mil for questions 
regarding the conditions of this approval and to discuss any substantive change to this activity, 
prior to implementation, to ensure such change does not impact the determination herein or 
compliance with the above References.   
4. In addition, please refer to the Terms of Air Force HRPO Approval referenced below 
regarding the responsibilities of the AF-supported Institution(s) and the Principal Investigator 
conducting this activity, to include reporting requirements to the HRPO. Failure to comply could 
result in suspension of Air Force support for this activity.  
5.  For questions regarding this HRPO review and approval, please contact Ms. Jill Conover, at 
(703) 681-8056 or via e-mail atjill.r.conover.ctr@mail.mil, Mr. Peter Marshall (E-
mail: peter.j.marshall.civ@mail.mil/phone:  703-681-6277/DSN  761)  or  usaf.pentagon.af-
sg.mbx.afmsa-sge-c@mail.mil.  
Peter Marshall, CIP 
Program Manager, AF Research Oversight & Compliance Division 
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Air Force Medical Readiness Agency (AFMRA/SGE-C) 
7700 Arlington Boulevard 
Falls Church, VA 22042 
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Appendix I: Costs Table and Project Timeline 
Table I-1 
Costs Table 
Element  Cost Time 
Equipment  0 $ 0 Hours 
Provider Care  0 $ 3 Hours 
Tech Care  0 $ 2 Hours 
Training  0 $ 1 Hour 
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Table I-2  
Project Timeline 
Task  Jan  Feb Mar Apr May Jun Jul Aug Sep Oct Nov 
Proposal  X 
defense 
 
IRB   X X 
 
Education  X X 
 
Provider   X X 
recruitment 
 
Patient     X 
recruitment 
 
Pre-A1C and    X 
DSMQ 
 
Implementation   X X X X 
 
Post-A1C, DSMQ,      X 
Provider Survey 
 
Data Analysis        X X 
 
Dissemination          X X 
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Appendix J: Permission to Use DSMQ 
SPECIAL TERMS 
These User License Agreement Special Terms (“Special Terms”) are issued between Mapi 
Research Trust (“MRT”) and Jonathan Beatty (“User”). 
These Special Terms are in addition to any and all previous Special Terms under the User 
License Agreement General Terms. 
These Special Terms include the terms and conditions of the User License Agreement General 
Terms, which are hereby incorporated by this reference as though the same was set forth in its 
entirety and shall be effective as of the Special Terms Effective Date set forth herein. 
All capitalized terms which are not defined herein shall have the same meanings as set forth in 
the User License Agreement General Terms. 
These Special Terms, including all attachments and the User License Agreement General Terms 
contain the entire understanding of the Parties with respect to the subject matter herein and 
supersedes all previous agreements and undertakings with respect thereto. If the terms and 
conditions of these Special Terms or any attachment conflict with the terms and conditions 
of the User License Agreement General Terms, the terms and conditions of the User License 
Agreement General Terms will control, unless these Special Terms specifically acknowledge the 
conflict and expressly states that the conflicting term or provision found in these Special Terms 
control for these Special Terms only. These Special Terms may be modified only by written 
agreement signed by the Parties. 
User information 
User name: Jonathan Beatty 
Category of User: Student 
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User address XXXXX 
User VAT number 
User email jrbeatty@alaska.edu 
User phone XXXXX 
Billing Address XXXXX 
General information 
Effective Date: Date of acceptance of these Special Terms by the User 
Expiration Date (“Term”): Upon completion of the Stated Purpose 
Name of User’s contact in charge of the request: Jonathan Beatty 
Identification of the COA 
© Mapi Research Trust, 2020. The unauthorized modification, reproduction and use of any 
portion of this document is prohibited. 
Name of the COA: DSMQ - Diabetes Self-Management Questionnaire 
Author Schmitt A. 
Copyright Holder Dr. Andreas Schmitt 
Copyright notice DSMQ © Dr Andreas Schmitt, 2013 
Bibliographic reference: 
Schmitt A, Gahr A, Hermanns N, Kulzer B, Huber J, Haak 
T. The Diabetes Self-Management Questionnaire (DSMQ): development and evaluation of an 
instrument to assess diabetes self-care activities associated with glycaemic 
control. Health Qual Life Outcomes. 2013 Aug 13;11:138 
 (Full Text Article) 
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Schmitt A, Reimer A, Hermanns N, Huber J, Ehrmann D, Schall S, Kulzer B. Assessing 
Diabetes Self-Management with the Diabetes Self-Management Questionnaire (DSMQ) Can 
Help Analyse Behavioural Problems Related to Reduced Glycaemic Control. PLoS One. 2016 
Mar 3;11(3)  
(Full Text Article) 
Modules/versions needed DSMQ 
Context of use of the COA 
The User undertakes to use the COA solely in the context of the Stated Purpose as defined 
hereafter. 
4.1 Stated Purpose 
Other project: 
Title: A TELEMEDICINE FOLLOW UP PROGRAM TO IMPROVE GLYCEMIC 
OUTCOMES FOR PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES 
Disease or condition Type II Diabetes 
Planned Term* Start: 04/01/2020; End: 12/30/2020 
Description (including format or media) Clinical quality improvement student DNP project on 
using telemedicine to improve glycemic outcomes 
4.2 Country and languages 
MRT grants the License to use the COA on the following countries and in the languages 
indicated in the table below: 
Version/Module Language For use in the following country  
© Mapi Research Trust, 2020. The unauthorized modification, reproduction and use of any 
portion of this document is prohibited. 
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DSMQ English the UK 
The User understands that the countries indicated above are provided for information purposes. 
The User may use the COA in other countries than the ones indicated above. 
5. Specific requirements for the COA 
The Copyright Holder of the COA has granted ICON LS exclusive rights to translate the COA in 
the context of commercial studies or any project funded by for-profit entities. ICON LS is the 
only organization authorized to perform linguistic validation/translation work on the COA. 
In case the User wants to use an e-Version of the COA, the User shall send the Screenshots of 
the original version of the COA to MRT or ICON LS for review and approval. The Screenshots 
review may incur additional fees.• 
In case the User wants to use an e-Version of the COA, ICON LS shall update (if needed) and 
populate the COA translations into the User’s or IT Company’s system and the User shall send 
the Screenshots of the translations of the COA to ICON LS for approval. The update (if needed), 
population of translations and the Screenshots review may incur additional fees. 
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